Title 2 U.S. Code of Federal Regulations Part 200 (Uniform Guidance) Reports For The Year Ended June 30, 2016

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

TABLE OF CONTENTS

	Page
INDEPENDENT AUDITORS' REPORT	1–2
CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2016 AND 2015:	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	4–5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7–37
SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2016	38–52
NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2016	53
REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH <i>GOVERNMENT AUDITING STANDARDS</i>	54–55
REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON THE SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE	56–58
SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2016	59–60



Deloitte & Touche LLP 250 East 5th Street Suite 1900 Cincinnati, OH 45202-5109 USA

Tel:+1 513 784 7100 Fax:+1 513 784 7204 www.deloitte.com

INDEPENDENT AUDITORS' REPORT

To the Board of Trustees Children's Hospital Medical Center and Affiliates: Cincinnati, Ohio

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Children's Hospital Medical Center and Affiliates ("Cincinnati Children's"), which comprise the consolidated balance sheets as of June 30, 2016 and 2015, and the related consolidated statements of operations and changes in net assets and of cash flows for the years then ended, and the related notes to the consolidated financial statements. The consolidated financial statements include the accounts of Children's Hospital Medical Center and the affiliated entities as discussed in Note 1(a). These entities are under common ownership and management.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Cincinnati Children's as of June 30, 2016 and 2015, and the consolidated results of their operations and their consolidated cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Other Information

Our audits were conducted for the purpose of forming an opinion on the basic consolidated financial statements taken as a whole. The accompanying schedule of expenditures of federal awards as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards, and the accompanying schedule is presented for the purposes of additional analysis and is not a required part of the basic consolidated financial statements.

The schedule of expenditures of federal awards is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic consolidated financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic consolidated financial statements or to the basic consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the basic consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 17, 2016 on our consideration of Cincinnati Children's internal control over financial reporting and our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Cincinnati Children's internal control over financial reporting and compliance.

Deloitte ? Touche LLP

October 17, 2016, Except for Note 12, as to which the date is January 27, 2017

Consolidated Balance Sheet June 30, 2016 and 2015 (dollars in thousands)

	2016	2015
CURRENT ASSETS:		
Cash and cash equivalents	\$ 148,913	\$ 125,267
Marketable securities	724,580	670,345
Cash, cash equivalents and marketable securities	873,493	795,612
Patient receivables, net of allowances of \$76,358 in 2016 and \$50,460 in 2015	353,783	317,831
Other receivables, net	130,524	173,788
Inventories and prepaid expenses	37,773	39,136
Total current assets	1,395,573	1,326,367
ASSETS LIMITED AS TO USE - Funds in trust	10,946	9,836
PROPERTY AND EQUIPMENT, net of accumulated depreciation	1,174,544	1,182,738
OTHER LONG-TERM ASSETS	58,695	61,432
INTEREST IN NET ASSETS OF SUPPORTING ORGANIZATIONS (Note 1(b))	1,377,455	1,319,739
Total assets	\$4,017,213	\$3,900,112
CURRENT LIABILITIES:		
Accounts payable and accrued expenses	\$ 244,057	\$ 330,020
Current portion of long-term debt and capital lease obligations	34,039	52,644
Total current liabilities	278,096	382,664
ACCRUED PENSION BENEFIT LIABILITY (Note 8)	421,695	229,252
SELF-INSURANCE RESERVES	38,235	42,338
LONG-TERM DEBT:		
Tax-exempt bonds payable	343,888	350,492
Taxable bonds payable	297,327	297,231
Notes payable	59,203	59,999
Capital lease obligations	6,466	4,286
OTHER LONG-TERM LIABILITIES	19,644	14,500
Total liabilities	1,464,554	1,380,762
COMMITMENTS AND CONTINGENCIES (Notes 5 and 9)	-	-
NET ASSETS:		
Unrestricted	1,036,207	1,060,125
Temporarily restricted	155,558	158,141
Permanently restricted (Note 1(b))	1,360,894	1,301,084
Total net assets	2,552,659	2,519,350
Total liabilities and net assets	\$4,017,213	\$3,900,112
See accompanying notes to consolidated financial statements.		

Consolidated Statements of Operations and Changes in Net Assets For the Years Ended June 30, 2016 and 2015 (dollars in thousands)

	2016	2015
UNRESTRICTED REVENUES, GAINS AND OTHER SUPPORT:		
Net hospital patient service revenue	\$1,611,570	\$1,547,131
Provision for bad debt	(13,703)	(19,195)
Net hospital patient service revenue less provision for bad debts	1,597,867	1,527,936
Capitation revenue	36,537	41,755
Net professional services revenue	299,516	295,871
Net assets released from restriction used for operations-		
Grant revenue	159,349	165,142
Other restricted net assets used to support operations	83,908	75,242
Investment income	25,469	9,131
Other revenue	107,991	91,393
Total unrestricted revenues, gains and other support	2,310,637	2,206,470
EXPENSES:		
Salaries	1,080,585	1,031,542
Employee benefits	270,163	256,525
Supplies, drugs and other	355,718	342,851
Purchased services	219,330	210,052
Depreciation	124,595	110,352
Utilities	18,537	18,988
Interest	24,883	19,425
Impairment of land	3,340	7,111
Total expenses	2,097,151	1,996,846
Excess of revenues over expenses	213,486	209,624
OTHER CHANGES IN UNRESTRICTED NET ASSETS: Receipts from supporting organizations (Notes 1(b) and 1(c))	4,150	4,033
Net assets released from restrictions used for purchase of property and equipment	1,066	10,639
Increase in unrestricted net assets before transfers to supporting organizations and pension and post	218 702	224 206
retirement health liability adjustment	218,702	224,296
Transfers to supporting organizations (Note 1(c))	(23,250)	(46,893)
Pension and post retirement health liability adjustment (Note 8)	(219,370)	(92,317)
(Decrease) Increase in unrestricted net assets	(23,918)	85,086

(Continued on next page)

Consolidated Statements of Operations and Changes in Net Assets For the Years Ended June 30, 2016 and 2015 (dollars in thousands)

	2016	2015
TEMPORARILY RESTRICTED NET ASSETS: Contributions and investment income-		
Grant receipts	158,447	164,730
Gifts, contributions and other income	83,583	91,430
	242,030	256,160
Net assets released from restriction-		
Grant expenditures	(159,349)	(165,142)
Transfer to The Children's Hospital	-	(1,000)
Restricted net assets used to support operations	(83,908)	(75,242)
Restricted net assets used for purchase of property and equipment	(1,066)	(10,639)
	(244,323)	(252,023)
(Loss) Gain in interest in net assets of supporting organizations	(290)	695
(Decrease) Increase in temporarily restricted net assets	(2,583)	4,832
PERMANENTLY RESTRICTED NET ASSETS:		
Gifts, contributions and other income	1,804	-
Gain in interest in net assets of supporting organizations	58,006	20,356
Increase in permanently restricted net assets	59,810	20,356
INCREASE IN NET ASSETS	33,309	110,274
NET ASSETS, beginning of year	2,519,350	2,409,076
NET ASSETS, end of year	\$2,552,659	\$2,519,350

See accompanying notes to consolidated financial statements.

Consolidated Statements of Cash Flows

For the Years Ended June 30, 2016 and 2015 (dollars in thousands)

_	2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES:		
Increase in net assets	\$ 33,309	\$ 110,274
Adjustments to reconcile increase in net assets to net cash provided by	\$ 22,2 09	¢ 110,=7 .
operating activities-		
Depreciation and amortization	125,292	110,687
Loss on disposal of property and equipment	3,035	2,518
Impairment of land	3,340	7,111
Proceeds from sale of donated securities	1,247	1,623
Receipts from supporting organizations	(4,150)	(4,033)
Contributions to supporting organizations	23,250	46,893
Contributions to supporting organizations Contributions restricted for purchase of property and equipment	(1,066)	(10,639)
Gain in interest in net assets of supporting organizations	(57,716)	(21,051)
Unrealized and realized losses (gains) on marketable securities, net	(10,443)	5,106
Increase (Decrease) in allowances on receivables	25,898	(3,799)
Increase in receivables		
	(18,586)	(47,512)
Decrease (Increase) in inventories and prepaid expenses and other assets	4,100	(9,661)
Decrease in accounts payable and accrued expenses	(34,756)	(8,872)
Increase (Decrease) in accrued pension liability	192,443	84,895
Increase (Decrease) in self-insurance reserves and other long-term	1.041	(5, 121)
liabilities	1,041	(5,434)
Net cash provided by operating activities	286,238	258,106
CASH FLOWS FROM INVESTING ACTIVITIES:		
Expenditures for property and equipment	(167,761)	(258,091)
Receipts from sale of fixed assets	750	582
Purchases of marketable securities	(1,891,387)	(1,633,044)
Sales and maturities of marketable securities	1,846,247	1,339,517
Cash withdrawn from funds in trust	41,755	61,991
Cash invested in funds in trust	(42,865)	(33,730)
Net cash used in investing activities	(213,261)	(522,775)
CASH FLOWS FROM FINANCING ACTIVITIES:		
	06 175	207 126
Issuance of bonds and notes payable	96,175	297,136
Repayment of bonds and notes payable	(127,472)	(31,809)
Contributions restricted for purchase of property and equipment	1,066	10,639
Receipts from supporting organizations	4,150	4,033
Contributions to supporting organizations	(23,250)	(46,893)
Net cash (used in) provided by financing activities	(49,331)	233,106
Net increase (decrease) in cash and cash equivalents	23,646	(31,563)
CASH AND CASH EQUIVALENTS, beginning of year	125,267	156,830
CASH AND CASH EQUIVALENTS, end of year	\$ 148,913	\$ 125,267
UPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES: apital expenditures in accounts payable and accrued expenses cquisition of property through capital leases	\$ 11,131 \$ 5,472	\$ 62,338 \$ 6,425

See accompanying notes to consolidated financial statements.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

(1) <u>Accounting Policies</u>-

(a) <u>Basis of Consolidation</u>--Children's Hospital Medical Center (Cincinnati Children's), River City Insurance Limited (River City), CHMC Community Health Services Network (CHSN), Northern Kentucky Children's Medical Services, LLC (NKCMS) (through October 31, 2015), Burnet Ave LLC (Burnet) and TSHCH LLC (TSHCH), which are under common management, are included in the accompanying consolidated financial statements and are collectively referred to as Cincinnati Children's or the Medical Center. Intercompany transactions and balances have been eliminated.

Cincinnati Children's is an Ohio not-for-profit corporation providing pediatric healthcare services, teaching and related research. River City is a captive insurance company and a wholly-owned subsidiary of Cincinnati Children's. CHSN is a wholly-owned subsidiary of Cincinnati Children's whose purpose is to manage primary care practices in a community setting. NKCMS is a limited liability corporation formed to enhance the scope and quality of pediatric care in Northern Kentucky. Effective October 31, 2015 NKCMS was dissolved. Burnet is a wholly-owned subsidiary of Cincinnati Children's, whose purpose is to hold land. TSHCH is a wholly-owned subsidiary of Cincinnati Children's whose purpose is to acquire, hold, develop, subdivide, sell, lease, mortgage, manage and otherwise deal in real property.

(b) <u>Supporting Organizations</u>--The Children's Hospital (TCH) and Convalescent Hospital for Children and Orphan Asylum (CHCOA), both Ohio not-for-profit corporations which are not included in the accompanying consolidated financial statements, provide financial support to Cincinnati Children's. Certain endowment funds of these supporting organizations are restricted by the donors for specific operating purposes of Cincinnati Children's and are recorded as Interest in Net Assets of Supporting Organizations in the accompanying Consolidated Balance Sheets. Receipts from such restricted endowment funds and certain other receipts that are designated by the Boards of Trustees of the supporting organizations for specific operating purposes are reflected as a component of restricted gifts and contributions in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Upon utilization in operations, such funds are reflected in the Consolidated Statements of Operations and Changes in Net Assets as other-restricted net assets used to support operations.

Other funds are contributed to Cincinnati Children's as designated by the Boards of the supporting organizations to provide general support and are reflected as receipts from supporting organizations in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

Cincinnati Children's records in its consolidated financial statements the fair value of certain temporarily and permanently restricted net assets held by supporting organizations on its behalf. Changes in the fair value of such temporarily and permanently restricted net assets are recorded as a Gain (Loss) in Interest in Net Assets of Supporting Organizations in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

Effective July 1, 2016, TCH's Board of Trustees amended their Articles of Incorporation naming Cincinnati Children's as its sole-beneficiary. The impact of this amendment is the Unrestricted Net Assets of TCH will be recorded in Cincinnati Children's consolidated financial statements as an increase in Interest in Supporting Organizations and an increase in Temporarily Restricted Net Assets. If the Unrestricted Net Assets of TCH would have been recorded in Cincinnati Children's consolidated financial statements at June 30, 2016, the impact would have been an increase to Interest in Supporting Organizations and an increase to Temporarily Restricted Net Assets of \$776,504.

(c) <u>Support Received from Supporting Organizations</u>-- In general, the supporting organizations provide annual support to Cincinnati Children's that includes the dividend and interest earnings of the respective investment portfolios (net of operational expenses and any donor required reinvestment of income). On occasion, the respective Boards of Trustees of these supporting organizations may also designate certain pledges of unrestricted principal in support of key projects at Cincinnati Children's. As of June 30, 2016, TCH and CHCOA have outstanding revocable pledges of \$250,000 and \$9,000, respectively. All outstanding pledges of principal support are revocable at the discretion of TCH's and CHCOA's Board of Trustees. As a result, such revocable pledges are not recorded as receivables in the accompanying consolidated financial statements.

During fiscal 2016 and 2015, TCH transferred \$55,201 and \$57,594, respectively, of temporarily restricted net assets to Cincinnati Children's which are recorded as Gifts, contributions and other income in the Consolidated Statements of Operations and Changes in Net Assets.

During fiscal 2016 and 2015, TCH transferred \$4,150 and \$4,033, respectively, of unrestricted net assets to Cincinnati Children's, which are recorded as Receipts from Supporting Organizations in the Consolidated Statements of Operations and Changes in Net Assets.

During fiscal 2015, Cincinnati Children's transferred \$1,000 of temporarily restricted net assets to TCH to fund named chairs designated to support divisional activities. There were no such transfers made in fiscal 2016. During fiscal 2016 and fiscal 2015, respectively, Cincinnati Children's transferred \$23,250 and \$46,893 of unrestricted net assets to TCH to fund named chairs designated to support divisional activities.

At June 30, 2015, Cincinnati Children's had a payable to TCH for \$3,022 related to transfers received greater than funding commitments in fiscal 2015. These amounts were offset in fiscal year 2016 against the current year commitment.

During fiscal 2016 and 2015, CHCOA transferred \$2,272 and \$10,922 respectively, to Cincinnati Children's which are recorded as Gifts, contributions and other income in the Consolidated Statements of Operations and Changes in Net Assets.

At June 30, 2016, Cincinnati Children's has a payable to CHCOA for \$20, which will be repaid through a reduction in support in fiscal 2017. At June 30, 2015 Cincinnati Children's had a payable to CHCOA for \$55 related to fiscal 2015 funding. This amount was paid in fiscal 2016.

At June 30, 2016 and 2015, Cincinnati Children's has a receivable from CHCOA for \$4,000 and \$6,395, respectively, related to an irrevocable pledge to be paid in fiscal years 2016 through 2018 in support of the renovation of the College Hill facility.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

At June 30, 2016 and 2015, Cincinnati Children's has a receivable from TCH of \$10,587 related to the expected payment from TCH upon maturity of a life insurance policy.

(d) <u>Concentration of Patient Accounts Receivable and Revenue and Revenue Recognition</u>--In both fiscal 2016 and 2015, respectively, substantially all of total net hospital patient service revenue is derived from third-party payment programs (Medicaid, insurance companies and various managed care agreements).

The following details the percentage of net hospital patient service revenue by payer category for the fiscal years ended June 30, 2016 and 2015:

	2016		2015	
	Gross	Net	Gross	Net
Commercial insurers	1%	2%	1%	2%
Managed care	45%	64%	43%	62%
Government (HMO and third party)	45%	25%	45%	24%
International	5%	6%	6%	7%
Specialty contracts	3%	3%	4%	5%
Self pay	1%	-	1%	-

The following details the percentage of accounts receivable by payer category as of June 30, 2016 and 2015:

	2016	2015
Commercial insurers	1%	3%
Managed care	43%	42%
Government (HMO and third party)	30%	27%
International	18%	20%
Specialty contracts	6%	6%
Self pay	2%	2%

Specialty contracts are single case agreements or contracts for specialty services, such as transplants.

Net hospital patient service revenue is reported at estimated net realizable amounts from patients, third party payers and others for services rendered and includes estimated retroactive revenue adjustments due to future audits and reviews. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits and reviews.

Cincinnati Children's recognizes net hospital patient service revenue associated with services provided to patients who have third-party payer coverage on the basis of estimated contractual rates for services rendered. For uninsured patients that do not qualify for charity care, Cincinnati Children's recognizes net hospital patient service revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy). On the basis of historical experience, a significant portion of Cincinnati Children's uninsured patients will be

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

unable or unwilling to pay for the services provided. Thus, Cincinnati Children's records a provision for bad debts related to uninsured patients in the period the services are provided.

Revenue from government (Medicaid and Medicare) programs accounted for approximately 25% and 24%, respectively, of Cincinnati Children's net hospital patient service revenue for the fiscal years ended June 30, 2016 and 2015, respectively. Laws and regulations governing the Medicaid and Medicare programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change a material amount in the near term. At June 30, 2016, Cincinnati Children's has settled all Medicaid cost reports through 2008 and all Medicare cost reports through 2014.

The following table reconciles gross patient service revenue to net hospital patient service revenue for the years ended June 30, 2016 and 2015:

	2016	2015
Charges at established rates	\$2,894,337	\$2,745,917
Deductions:		
Discounts on commercial contractuals	(335,402)	(322,169)
Write-downs related to services to the poor:		
Including Medicaid and governmental		
contractuals, charity care and other		
uncollectible self pay write-offs	(978,838)	(906,572)
	1,580,097	1,517,176
Tax Levy Program	4,950	5,200
Care Assurance Program	26,523	24,755
Net Hospital Patient Service Revenue	\$1,611,570	\$1,547,131

Patient accounts receivable and related allowances for contractual adjustments and doubtful accounts are recorded on an accrual basis at estimated collection rates to report patient accounts receivable at net realizable value. Accounts receivable are reduced by an allowance for doubtful accounts and contractual allowances. In evaluating the collectability of accounts receivable. Cincinnati Children's performs a detail review of current accounts, analyzes its past history and identifies trends for each of its major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and contractual allowances. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowances. For receivables associated with services provided to patients who have a third-party coverage, Cincinnati Children's analyzes contractually due amounts and provides an allowance for contractuals (for example, for expected unrecoverable amounts based on contract provisions on accounts for which the third-party payer has not yet paid, or for payers who are known to be having financial difficulties that make the realization of amounts due unlikely). For receivables associated with self-pay patients (which includes both patients without insurance and patients with deductible and copayment balances due for which third-party coverage exists for part of the bill), Cincinnati Children's records a provision for bad debts in the period of service on the basis of its past experience, which indicates that many patients are unable or unwilling to pay the portion of their bill for which they are financially responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

reasonable collection efforts have been exhausted is charged off against the allowance for doubtful accounts.

Cincinnati Children's allowance for doubtful accounts for self-pay patients was 21.5% and 17% of self-pay accounts receivable at June 30, 2016 and 2015. In addition, Cincinnati Children's bad debt write-offs (before recoveries) totaled approximately \$27,302 and \$31,805 for the years ended June 30, 2016 and 2015, respectively. Cincinnati Children's does not maintain a material allowance for doubtful accounts from third-party payers nor does it have significant write-offs from third-party payers. Cincinnati Children's does maintain an allowance for contractual write-offs for third party payers in order to appropriately reduce receivables to net realizable value.

A summary of activity in Cincinnati Children's provision for doubtful accounts for the year ended June 30, 2016 and 2015 related to patient receivables is as follows:

Year Ended June 30, 2016	Balance at Beginning of <u>Year</u> \$12,140	Provision for doubtful <u>Accounts</u> \$13,669	Accounts written off, Net <u>of recoveries</u> \$(13,125)	Balance at End <u>of Year</u> \$12,684
Year Ended June 30, 2015	\$15,139	\$15,389	\$(18,388)	\$12,140

The Consolidated Balance Sheet also includes \$63,674 and \$38,320 of contractual reserves related to net patient receivables as of June 30, 2016 and 2015.

Accounts receivable related to professional services billings is included in Other Receivables in the accompanying Consolidated Balance Sheets.

- (e) <u>Capitation Revenue</u> Cincinnati Children's has agreements with two Ohio Medicaid managed care companies, covering approximately 31,000 and 33,000 children, respectively, in fiscal 2016 and fiscal 2015, to provide for reimbursement under a variable capitation methodology for hospital services. Under these two contracts, all physician and home care services continue to be reimbursed based on provider fee schedules. The hospital services are reimbursed through a variable capitation payment which represents the amount remaining after payment has been made for (a) Cincinnati Children's physician services, (b) Cincinnati Children's home care services, and (c) services provided to members outside the Cincinnati Children's network. Under delegation agreements, Health Network by Cincinnati Children's receives fixed payments to perform the required medical management, care management and care coordination functions. Medicaid managed care organizations retain risk for payments to providers.
- (f) <u>Grant Revenue and Other Revenue</u> -- Grants and contributions restricted for a specific operating purpose are recorded as temporarily restricted net assets and reflected in unrestricted revenues, gains, and other support when the funds are expended in accordance with the specifications of the grantor or donor. Contributions for capital expenditures, recorded as temporarily restricted net assets when received, are recorded as net assets released from restrictions used for the purchase of property and equipment when expended. Unrestricted contributions and bequests are included in other revenue when received.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

- (g) <u>Graduate Medical Education</u>--Cincinnati Children's receives Federal graduate medical education funding, which has resulted in other revenue of \$10,209 and \$9,209 recognized in the accompanying consolidated financial statements for the years ended June 30, 2016 and 2015, respectively.
- (h) <u>Tax Exempt Status</u>--Cincinnati Children's and CHSN are recognized by the Internal Revenue Service as exempt from federal income taxes under Section 501(a) of the Internal Revenue Code as charitable organizations qualifying under Section 501(c)(3). River City is a captive insurance company and has no income tax obligations. NKCMS, Burnet and TSHCH are limited liability corporations whose income is taxable to Cincinnati Children's. The income tax provisions recorded in the accompanying consolidated financial statements are immaterial for the years ended June 30, 2016 and 2015.

Cincinnati Children's accounts for income taxes in accordance with Accounting Standards Codification Topic (ASC) 740 "Income Taxes". It is Cincinnati Children's policy to classify the expense related to interest and penalties, if any, to be paid on underpayments of income taxes within other expenses. There were no material penalties or interest recognized in fiscal 2016 and 2015.

Listed below are the tax years that remain subject to examination by major tax jurisdiction:

Federal – 2013 to 2016 State – 2013 to 2016

- (i) <u>Cash Equivalents</u>--Cash equivalents consist primarily of money market investments (including money market mutual funds), certificates of deposit and demand deposits. Cash is held primarily in one bank.
- (j) <u>Inventories</u>-Inventories consist of medical supplies and pharmaceuticals and are valued on an average cost method.
- (k) <u>Marketable Securities</u>-- Cincinnati Children's accounts for its investments under ASC 958-320 "Not-for-Profit Entities Investments Debt and Equity Securities". Cincinnati Children's carries its marketable securities at fair value with unrealized gains and losses included in investment income in the accompanying Consolidated Statements of Operations and Changes in Net Assets. At June 30, 2016, there were \$1,662 and \$1,555 of pending purchases and sales of marketable securities, respectively. At June 30, 2015, there were \$3,729 and \$20,678 of pending purchases and sales of marketable securities, respectively.

At June 30, 2016, Cincinnati Children's marketable securities included 17% in U.S Treasury securities. At June 30, 2015, Cincinnati Children's marketable securities included 15% in U.S. Treasury securities.

(l) <u>Assets Limited As To Use</u>--Assets limited as to use include funds in trust (Note 3). Assets limited as to use are carried at fair value with unrealized gains and losses included in investment income in the accompanying Consolidated Statements of Operations and Changes in Net Assets. At June 30, 2016 and 2015, assets limited as to use were invested in cash and cash equivalents.

Consolidated Financial Statements

For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

(m) <u>Investment Income</u>--The following details the components of investment income on marketable securities and funds in trust for the years ended June 30, 2016 and 2015:

	2016	2015
Interest income	\$15,026	\$14,237
Unrealized and realized gains (losses), net	10,443	(5,106)
Investment income	\$25,469	\$9,131

Unrealized gains and losses related to temporarily restricted funds are recorded as an addition/reduction, as appropriate, to temporarily restricted net assets.

(n) <u>Fair Value Measurements</u>—Cincinnati Children's accounts for its assets and liabilities under ASC 820 "Fair Value Measurements". As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three broad levels, which are described below:

Level 1: Quoted Prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date for assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. These include quoted prices for identical or similar assets or liabilities in markets that are not active, that is, markets in which there are a few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers, or in which little information is released publicly and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3: Unobservable inputs, developed using Cincinnati Children's estimates and assumptions, which reflect those that the market participants would use. Such inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Determining where an asset or liability falls within the hierarchy depends on the lowest level input that is significant to the fair value measurement as a whole. In determining fair value, Cincinnati Children's utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in the assessment of fair value.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

The table below includes the major categorization for debt and equity securities on the basis of the nature and risk of the investments at June 30, 2016.

	Level 1	Level 2	Level 3
Marketable Securities:			
U.S. Government and agency securities	\$ -	\$215,984	\$ -
Foreign bonds	-	4,780	-
Municipal bonds	-	3,590	-
Common stock	254	-	-
Corporate obligations	-	481,633	-
High Yield Corporate Obligations	-	18,339	-
0000	254	724,326	
Assets Limited As To Use:		/,0_0	
Money market mutual funds	10,946	-	-
2	10,946		
Deferred Compensation Plans (included in Other Assets):			
Cash	2,992	-	-
Common stock	3,556	-	-
Mutual Funds:	-,		
Money Market	104	-	-
Equity	1,240	-	-
International Equity	874	-	-
Bond	596	-	-
Lifecycle	3,325	-	-
Real Estate	205	-	-
Variable Annuities:			
Bond	-	22	-
Equity	-	274	-
International Equity	-	105	-
Money Market	-	43	-
Guaranteed Insurance			2,321
	12,892	444	2,321
Total	\$24,092	\$724,770	\$2,321

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

The table below includes the major categorization for debt and equity securities on the basis of the nature and risk of the investments at June 30, 2015.

	Level 1	Level 2	Level 3
Marketable Securities:			
U.S. Government and	\$ -	\$197,909	\$
agency securities			-
Foreign bonds	-	6,462	-
Municipal bonds	-	2,790	-
Bond mutual funds	1,864	-	-
Common stock	170	-	-
Asset backed securities	-	28,392	-
Corporate obligations		432,758	
	2,034	668,311	
Assets Limited As To Use:			
Money market mutual funds	9,836		
	9,836	-	-
Deferred Compensation Plans			
(included in Other Assets):			
Cash	2,386	-	-
Common stock	3,534	-	-
Mutual Funds:			
Money Market	145	-	-
Equity	2,921	-	-
International Equity	1,095	-	-
Bond	1,342	-	-
Lifecycle	3,434	-	-
Real Estate	268	-	-
Variable Annuities:			
Bond	-	98	-
Equity	-	324	-
International Equity	-	128	-
Money Market	-	18	-
Guaranteed Insurance			2 060
Contract	-	-	3,069
	15,125	568	3,069
Total	\$26,995	\$668,879	\$3,069

The valuation methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in different fair value measurement at the reporting date.

Cincinnati Children's uses quoted market prices in active markets to determine the fair value of common stock and mutual funds; such items are classified as Level 1 in the fair value hierarchy.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

Cincinnati Children's primarily bases fair value for investments in fixed income securities, including US government securities, municipal bonds and corporate obligations on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate) and considers the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy.

Investments in private investment funds are valued by net asset value, as published and determined by the fund manager.

Cincinnati Children's investment in High Yield Corporate Obligations is an investment in a limited liability company whose investment objective is to achieve superior fixed income returns on invested funds through exposure to higher quality, less volatile, high yield debt securities. As set forth in the LLC agreement, the LLC will dissolve on March 29, 2040, but may dissolve earlier under certain conditions. Any Investing Member may elect to withdraw, in whole or in part from the LLC on the last business day of any month or at such other date, as determined by the manager.

ASC 825 permits entities to choose to measure many financial instruments and certain other items at fair value. Entities that elect the fair value option will report unrealized gains and losses in earnings at each subsequent reporting date. Cincinnati Children's elected to measure its high yield corporate obligation investment fund under the provisions of ASC 825. In the future, Cincinnati Children's may elect to measure certain additional financial instruments at fair value in accordance with this standard.

The guaranteed insurance contract is recorded based on discounted cash flows, which is an approximation of fair value.

Cincinnati Children's Level 3 investment is primarily in a guaranteed insurance contract. This investment is classified as Level 3 based on time restrictions for redemption.

The following is a reconciliation of the roll forward of the fair value measurements using significant unobservable inputs for fiscal 2016:

Balance at July 1, 2015	\$3,069
Purchases	1,205
Unrealized losses	(24)
Sales	(1,929)
Balance at June 30, 2016	\$2,321
The amount of total gains or losses for the	
period included in changes in net assets	
attributable to the change in unrealized gains or	
losses related to assets still held at June 30,	
2016	\$ (24)

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

The following is a reconciliation of the roll forward of the fair value measurements using significant unobservable inputs for fiscal 2015:

Balance at July 1, 2014	\$5,251
Purchases	1,266
Unrealized losses	(112)
Sales	(3,336)
Balance at June 30, 2015	\$3,069
The amount of total gains or losses for the	
period included in changes in net assets	
attributable to the change in unrealized gains or	
losses related to assets still held at June 30,	
2015	\$(112)

Cincinnati Children's policy is to recognize transfers in and out as of the actual date of the event or change in circumstances that caused the transfer. For the years ended June 30, 2016 and 2015, there were no significant transfers in or out of Levels 1, 2 or 3.

(o) <u>Property and Equipment</u>--Property and equipment are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, ranging from three to forty years, as follows:

Land Improvements	3-25 years
Buildings and Building Improvements	5-40 years
Equipment	3-25 years

Amortization of assets leased under capital leases is included in depreciation.

Cincinnati Children's evaluates long-lived assets under the provisions of ASC 360 "Property Plant and Equipment". During fiscal 2016 and 2015, Cincinnati Children's recorded losses of \$3,340 and \$7,111, respectively, related to impairment of land values based on a fair market value assessment of the estimated sales price Cincinnati Children's would expect to receive upon sale of this land.

(p) <u>Costs of Borrowing</u>--Interest incurred on borrowed funds, net of interest earned on restricted bond funds, during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. In fiscal 2016 and fiscal 2015, Cincinnati Children's capitalized \$48 and \$843 of interest related to construction in progress. Total cash paid for interest was approximately \$24,975 and \$18,720 and in fiscal 2016 and 2015, respectively.

Deferred bond issuance costs and original issue discounts are amortized using the effective interest method over the period the related obligation is outstanding.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

(q) <u>Temporarily Restricted Net Assets</u>--Temporarily restricted net assets are those whose use by Cincinnati Children's has been limited by donors to a specific purpose. Temporarily restricted net assets and net assets released from donor restrictions are primarily comprised of net assets restricted to support operations. Substantially all of these net assets are restricted by donors to support research, education and other advances in clinical care and prevention. The amount of temporarily restricted net assets whose use by Cincinnati Children's has been limited by donors for a specific purpose was \$137,194 and \$139,486 at June 30, 2016 and 2015, respectively.

Temporarily restricted net assets related to assets held in endowments at supporting organizations on Cincinnati Children's behalf are either donor restricted to support research at Cincinnati Children's or deferred gift programs where the restriction is a time restriction tied to the life expectancy of the donor. The amount of temporarily restricted net assets held at supporting organizations was \$18,364 and \$18,655 at June 30, 2016 and 2015, respectively.

(r) <u>Permanently Restricted Net Assets</u>— Permanently restricted net assets related to assets held at Cincinnati Children's are gifts to Cincinnati Children's restricted by the donor to be maintained in perpetuity and are recorded in Assets Limited to Use in the accompanying Consolidated Balance Sheets. The amounts of permanently restricted net assets held at Cincinnati Children's with expendable investment income restricted by donors was \$1,803 and \$0 at June 30, 2016 and 2015, respectively. The assets underlying Cincinnati Children's permanently restricted net assets held at Cincinnati Children's are primarily cash and cash equivalents.

Permanently restricted net assets related to assets held in endowments at supporting organizations on Cincinnati Children's behalf are restricted by the donor to be maintained in perpetuity and are recorded in Interest in Net Assets of Supporting Organizations in the accompanying Consolidated Balance Sheets as they are held by supporting organizations. The amount of permanently restricted net assets held at supporting organizations with expendable investment income restricted by donors was \$1,359,091 and \$1,301,084 at June 30, 2016 and 2015, respectively. The assets underlying Cincinnati Children's permanently restricted net assets held by supporting organizations have been invested primarily in marketable securities.

As of June 30, 2016 and 2015, permanently restricted net assets consisted of the following amounts with expendable investment income restricted by donors to be used for the following purposes:

	2016	2015
Research activities	\$1,159,700	\$1,098,777
Clinical activities	201,194	202,307
	\$1,360,894	\$1,301,084

(s) Excess of Revenues Over Expenses--The Consolidated Statements of Operations and Changes in Net Assets include "excess of revenues over expenses." Changes in unrestricted net assets which are excluded from excess of revenues over expenses include receipts from supporting organizations, transfers to supporting organizations, pension and post retirement health liability adjustment, and contributions of long-lived assets (including assets acquired using contributions which by donor restrictions were to be used for the purpose of acquiring such assets).

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

- (t) <u>Use of Estimates</u>--The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
- (u) <u>New Accounting Pronouncements</u> In May 2014, the FASB issued ASU 2014-09 "Revenue from Contracts with Customers (Topic 606)." ASU 2014-09 will eliminate the transaction- and industryspecific revenue recognition guidance currently in place under generally accepted accounting principles and will replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 was amended by ASU 2015-14 and will be effective for annual and interim periods beginning after December 15, 2018, and early adoption is prohibited.

Furthermore, ASU 2014-09 and ASU 2015-14 were further amended in March 2016 with ASU 2016-08 "Principal versus Agent Considerations," in April 2016 with ASU 2016-10 "Identifying Performance Obligations and Licensing," and in May 2016 with ASU 2016-12 "Narrow-Scope Improvements and Practical Expedients." The amendments have the same effective date and transition requirements as the new revenue standard in ASU 2014-09 and ASU 2015-14. Management has not yet evaluated the impact of the revenue accounting standard updates, ASU 2014-09, ASU 2015-14, ASU 2016-08, ASU 2016-10, and 2016-12.

In April 2015, the FASB issued ASU 2015-03 "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 requires debt issuance costs to be presented on the balance sheet as a direct deduction from the carrying amount of the debt liability. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015. Earlier adoption is permitted, and Cincinnati Children's has adopted this guidance as of June 30, 2016. \$5,420 and \$5,687 were reclassified from Other Long Term Assets to offset against applicable Long Term Debt in fiscal 2016 and fiscal 2015, respectively.

In May 2015, the FASB issued ASU 2015-07 "Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent)." The amendments remove the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The amendments also remove the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. ASU 2015-07 will be effective for fiscal years beginning after December 15, 2016, with application applied retrospectively; earlier application is permitted. Management does not believe this will have a material impact on the consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02 "Leases." ASU 2016-02 introduces a new lessee model that brings substantially all leases onto the balance sheet. Most of the existing lessor principles are retained, but ASU 2016-02 aligns many of those principles with the FASB's new revenue guidance. ASU 2016-02 will be effective for fiscal years beginning after December 15, 2018 with modified retrospective transition; early adoption permitted. Management has not yet evaluated the impact of ASU 2016-02 on the consolidated financial statements.

In August 2016, the FASB issued ASU 2016-14 "Presentation of Financial Statements for Not-for-Profit Entities." The amendments focus on improving reporting in areas unique to not-for-profit

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

financial statements. Temporarily restricted and permanently restricted net assets are combined into a single category called "net assets with donor restrictions." Donor-restricted endowment funds that are underwater are reported in net assets with donor restrictions and require enhanced disclosures. Additional disclosures are required around liquidity of financial assets, internal transfers included in the operating subtotal, the nature of expenses, and cost allocation between program and support functions. Lastly, investment expenses netted with investment return are limited to external investment expenses and direct internal investment expenses. ASU 2016-14 will be effective for fiscal years beginning after December 15, 2017, with application applied retrospectively; early adoption is permitted. Management has not yet evaluated the impact of ASU 2016-14 on the consolidated financial statements.

(2) Losses on the Provision of Uncompensated Care-

In accordance with its mission and purpose, Cincinnati Children's maintains a policy of providing medically necessary services to pediatric patients within its primary service area regardless of ability to pay. This primary service area has been defined to include the four counties in Ohio, three counties in Kentucky and one county in Indiana that geographically surround Cincinnati. Under certain circumstances, Cincinnati Children's accepts patients from outside the primary service area regardless of their ability to pay. Cincinnati Children's defines indigent patient care as services rendered to patients whose families' annual income or net worth falls below certain minimum standards. As such, losses absorbed by the Medical Center in rendering services to patients who are covered under governmental programs which are designed to aid low income families (primarily the Medicaid program) are considered indigent patient care.

Consolidated Financial Statements

For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

The following information summarizes uncompensated care provided during the years ended June 30, 2016 and 2015:

2016 CHARGES	Hospital	Physician	Total
Charges under Medicaid and other entitlement programs	\$1,308,262	\$288,106	\$1,596,368
Charity care not eligible for Medicaid assistance, at established charges	29,290	3,682	32,972
Other uncollectible self pay, at established charges	13,703	8,438	22,141
Total Medicaid, charity care and other uncollectible self pay charges	\$1,351,255	\$300,226	\$1,651,481
COSTS/LOSSES			
Estimated costs to provide uncompensated care Reimbursement from Medicaid programs	\$ 606,333 (446,443)	\$ 141,857 (35,006)	\$ 748,190 (481,448)
Losses on the provision of uncompensated care Funds received from HCAP and tax levy	(159,890) 31,473	(106,851)	(266,742) 31,473
Losses on provision of uncompensated care net of HCAP and tax levy	\$(128,417)	\$(106,851)	\$(235,269)
2015	TT 1 / 1		
CHARGES	Hospital	Physician	Total
Charges under Medicaid and other entitlement	\$1,247,823	¢700 577	¢1 526 206
programs	\$1,247,025	\$288,573	\$1,536,396
Charity care not eligible for Medicaid assistance, at established charges	26,324	\$288,373 3,266	\$1,536,396 29,590
Charity care not eligible for Medicaid assistance, at established charges Other uncollectible self pay, at established charges			
Charity care not eligible for Medicaid assistance, at established charges Other uncollectible self pay, at established	26,324	3,266	29,590
Charity care not eligible for Medicaid assistance, at established charges Other uncollectible self pay, at established charges Total Medicaid, charity care and other	26,324 19,195	3,266 9,526	29,590 28,721
Charity care not eligible for Medicaid assistance, at established charges Other uncollectible self pay, at established charges Total Medicaid, charity care and other uncollectible self pay charges	26,324 19,195	3,266 9,526	29,590 28,721
Charity care not eligible for Medicaid assistance, at established charges Other uncollectible self pay, at established charges Total Medicaid, charity care and other uncollectible self pay charges	26,324 19,195 \$1,293,342	3,266 9,526 \$301,365	29,590 28,721 \$1,594,707
Charity care not eligible for Medicaid assistance, at established charges Other uncollectible self pay, at established charges Total Medicaid, charity care and other uncollectible self pay charges COSTS/LOSSES Estimated costs to provide uncompensated care	26,324 <u>19,195</u> <u>\$1,293,342</u> <u>\$572,923</u>	3,266 9,526 \$301,365 \$ 143,600	29,590 28,721 \$1,594,707 \$ 716,523

The 2016 and 2015 cost amounts reflected in the tables above are calculated using cost to charge ratios calculated from prior year cost reports as the current year cost report is not yet available. Management does not believe that the difference in the cost report year would have a material impact on the amounts calculated.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

(3) Funds in Trust-

Cincinnati Children's has certain funds, which are invested and held in trust for various specified purposes. The amounts of such funds, at carrying value, and the specified purposes for which such funds may be used, are set forth below:

	June 30,	
	2016	2015
Self-insurance Funds-		
Professional liability (A)	\$ 160	\$ 161
Employee health and workers' compensation (B)	230	890
Health Network Escrow (C)	2,642	2,641
Bond interest escrow funds (D)	6,111	6,144
Endowment funds held at Cincinnati Children's (E)	1,803	
	\$10,946	\$ 9,836

- (A) Cincinnati Children's has established an irrevocable trust fund for the payment of professional liability claim settlements. See Note 5 for further discussion of professional liability selfinsurance.
- (B) Cincinnati Children's has established a trust fund for the payment of claims related to certain selfinsured employee health care and other programs.
- (C) Cincinnati Children's maintains an escrow fund with a bank as part of the arrangement with an Ohio Medicaid Managed Care Company under its division called Health Network to cover estimated incurred but not reported claims for Cincinnati Children's providers, home care and mental health services as well non-Cincinnati Children's providers.
- (D) Cincinnati Children's maintains bond interest escrow funds as required under the terms of the related bond indentures to hold interest payments until the required payment dates to bondholders.
- (E) Cincinnati Children's holds endowment funds related to permanently restricted assets gifted directly to Cincinnati Children's.

Consolidated Financial Statements

For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

(4) Property and Equipment-

Property and equipment consists of the following:

	June 30,	
	2016	2015
Land	\$ 37,885	\$ 37,763
Land improvements	27,650	21,343
Buildings and building improvements	1,473,622	1,353,957
Equipment	604,897	585,432
Construction in progress	54,143	119,908
	2,198,197	2,118,403
Accumulated depreciation	(1,023,653)	(935,665)
Property and equipment, net	\$ 1,174,544	\$1,182,738

(5) Professional Liability-

The Medical Center's insurance program includes a self-insured retention for losses arising out of healthcare professional liability claims. The self-insured retention for the claims that are currently asserted is as follows:

30

For claims made between:	
October 1, 2004 and September 30, 2006	\$10,000 (\$20,000 in aggregate)
For claims made subsequent to:	
October 1, 2006	\$10,000 (\$25,000 in aggregate)

During this same time period, the Medical Center annually purchased excess healthcare professional liability insurance on a claims made basis at varying levels.

The actuarial present value of expected costs (including incurred, but not reported claims) for the healthcare professional liability program of \$38,483 and \$41,656 for 2016 and 2015, respectively, has been accrued in the accompanying Consolidated Balance Sheets. Accrued healthcare professional liability losses have been discounted at a rate of approximately 4% at June 30, 2016 and 2015, respectively. The costs of the Medical Center's healthcare professional liability program, including premiums paid for excess re-insurance, legal fees, settlements, judgments, and other administrative costs are included in Supplies, Drugs and Other in the accompanying Consolidated Statements of Operations and Changes in Net Assets. On an ongoing basis, management reviews the status of all healthcare professional liability claims, as well as legal proceedings, and, based upon consultation with a professional actuary, adjusts the accrued losses and self-insured retention funding levels to reflect its best estimate of the present value of expected costs for the healthcare professional liability claims. Healthcare professional liability expense amounted to \$3,418 and \$5,961 for fiscal 2016 and 2015, respectively.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

(6) Capital Lease Obligations-

The Medical Center leases certain equipment under capital leases. The aggregate future minimum lease payments total \$9,262, with \$2,403 due in fiscal 2017. In fiscal 2016 and 2015, Cincinnati Children's entered into ten and six, respectively, capital leases for certain equipment.

Consolidated Financial Statements

For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

(7) Bonds Payable and Notes Payable-

Bonds payable and notes payable for the years ended June 30, 2016	and 2015 consist o 2016	of the following: 2015
Bonds payable and notes payable:		
Series 1997, variable interest (0.42% at June 30, 2016), due		
through 2017	\$ 9,072	\$17,869
Series 2000, variable interest, due through 2028	-	46,954
Series 2002, variable interest (0.42% at June 30, 2016), due		
through 2028	17,243	18,363
Series 2006, 4.25% to 5.00%, due through 2032, net of		-
unamortized premium of \$360 in 2016 and \$373 in 2015	62,416	62,384
Series 2007, variable interest, due through 2037	-	30,472
Series 2008, variable interest, due through 2036	-	18,938
Series 2009, 4.20% due through 2019	8,977	11,970
Series 2010, 2.27% due through 2020	11,974	14,967
Series 2011, 2.18% due through 2022	41,875	45,125
Series 2014S, 3.0% to 5.0% due through 2034, net of		
unamortized premium of \$7,679 in 2016 and \$9,027 in		
2015	121,021	126,781
Series 2014T, 4.268% due 2044, taxable	297,327	297,231
Series 2016U, variable interest (0.99% at June 30, 2016), due		
through 2026	46,515	-
Series 2016V, variable interest (0.82% at June 30, 2016), due		
through 2037	30,615	-
Series 2016W, variable interest (0.82% at June 30, 2016), due		
through 2036	19,045	-
Term Note Payable, 2.20% due through 2022	36,000	42,000
Note Payable on Vernon Manor Property I, interest at 6.392%	24,289	25,301
Note Payable on Vernon Manor Property II	5,685	-
Total bonds payable and notes payable	732,054	758,355
Less- current portion	(31,636)	(50,633)
Bonds payable and notes payable - long-term	\$700,418	\$707,722

(a) <u>Tax Exempt Bonds Payable</u>—Cincinnati Children's has pledged their gross revenues, as defined, to secure the payment of Series 1997, 2002, 2006, 2009, 2010, 2011, 2014S, 2014T, 2016U, 2016V, 2016W bonds. Cincinnati Children's is bound by certain financial covenants included in the bond indentures, letters of credit (fully securing the 1997 and 2002 issuances), direct placement agreements, and related agreements. Among other restrictions is a requirement to maintain a minimum Debt Service Coverage Ratio, as defined.

Payment of the principal of, and the interest on, the Series 2006 bonds is insured by a policy of municipal bond insurance. The 1997 and 2002 bonds may be tendered to a remarketing agent by bondholders on business days for full payment of principal and accrued interest. Cincinnati Children's has entered into standby letters of credit totaling \$27,444 which commits financial institutions to make funds available to purchase the bonds that are not remarketed. Cincinnati Children's is required to maintain these or similar agreements until the bonds have been paid or converted to fixed rate obligations. The letter of credit that secured the 2008 bond issuance expired in

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

June 2016 which required reclassification of the full balance \$19,045 to current liabilities for the fiscal year ended June 30, 2015.

The interest rates on the 1997 and 2002 variable rate bonds are reset weekly by a rate-setting agent. The interest rates on the 2016U, 2016V, and 2016W variable rate bonds are reset monthly by the financial institution in accordance with the terms of the direct placement agreements.

(b) <u>Early Extinguishment of Bonds Payable</u> – In June 2016, Cincinnati Children's legally defeased \$46,515 of the outstanding 2000 bonds with the issuance of tax-exempt direct private placement obligations (2016U). The obligations bear interest at a variable rate (70% of LIBOR + 67 basis points) and mature in fiscal 2026.

In June 2016, Cincinnati Children's legally defeased 30,615 of the outstanding 2007M bonds with the issuance of tax-exempt direct private placement obligations (2016V). The obligations bear interest at a variable rate (70% of LIBOR + 59 basis points) and mature in fiscal 2037.

In June 2016, Cincinnati Children's legally defeased \$19,045 of the outstanding 2008O bonds with the issuance of tax-exempt direct private placement obligations (2016W). The obligations bear interest at a variable rate (70% of LIBOR + 50 basis points) and mature in fiscal 2036.

In connection with the retirement of the bonds, Cincinnati Children's wrote off \$319 of deferred bond costs.

(c) <u>Future Debt Maturities</u> ---

The following is a schedule of future debt maturities, excluding discounts/premiums and deferred issuance costs:

2017	\$ 31,636
2018	33,796
2019	26,687
2020	31,565
2021	25,929
Thereafter	579,382
	\$728,995

- (d) <u>Lines of Credit</u> In June 2016 Cincinnati Children's entered into a new 5 year agreement to increase the line of credit from \$150,000 to \$200,000. The line of credit expires in June 2021 and bears interest at the greater of the prime rate, federal funds rate plus .50% or the sum of LIBOR plus 1.00%. Prior to June 2016, Cincinnati Children's had a line of credit of \$150,000 bearing interest at LIBOR plus 65 basis points. There were no draws on the line of credits during fiscal 2016 and 2015.
- (e) <u>Note Payable on Vernon Manor Property I</u> -- Cincinnati Children's entered into an agreement with a Developer to renovate and occupy the Vernon Manor property to be used primarily for administrative office space. Additionally, a parking garage was constructed on adjacent property in order to provide

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

parking for the occupants of the building. As part of the agreement, Cincinnati Children's agreed to make fixed monthly payments over the seventeen year term of the agreement. In fiscal 2016, Cincinnati Children's agreed to a 4 year extension of the agreement to expire in fiscal 2032. The present value of such fixed payments at June 30, 2016 and 2015 is \$24,289 and \$25,301, respectively, using Cincinnati Children's estimated tax-exempt interest rate at the time of the agreement of 6.392%. The agreement also calls for variable payments monthly to cover operating expenses for the office building and the parking garage.

(f) <u>Note Payable on Vernon Manor Property II</u> – In November 2015, Cincinnati Children's entered into an agreement with a Developer to build and occupy property to be used primarily for parking and administrative office space. The property is adjacent to the existing Vernon Manor building. As part of the agreement, Cincinnati Children's agreed to make fixed monthly payments over the 15 year term of the agreement at commencement of the lease, which will not occur until summer 2017. At June 30, 2016, Cincinnati has recorded \$5,685 in construction in progress and note payable related to this project. The agreement also calls for variable payments monthly to cover operating expenses for the office building and the parking garage.

(8) Employee Benefit Plans-

Cincinnati Children's maintains non-contributory retirement plans covering substantially all employees. Among these plans is a defined benefit plan where benefits are based on a formula which reflects years of service and salary levels. Cincinnati Children's funding policy for its defined benefit plan meets the funding standards established by the Employee Retirement Income Security Act of 1974 (ERISA).

Cincinnati Children's investment strategy with respect to pension assets is designed to achieve a moderate level of overall portfolio risk in keeping with desired risk objective, which is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Cincinnati Children's adopted an Investment Policy that adjusts allocations based on the funded status of the Plan and prevailing yields. As funded ratio improves, allocations to fixed income increase accordingly. Based on a funded ratio of less than 80% at June 30, 2016, the portfolio contains a target allocation as follows:

US Investment Grade Fixed Income (Core and Long Duration)	20.0%
High Yield Fixed Income	5.0%
Emerging Markets Fixed Income	5.0%
Global Developed Markets Equity	45.0%
Emerging Markets Equity	12.0%
Private Equity	6.0%
Real Estate	6.0%
Cash	1.0%

In order to maintain the portfolio's actual asset allocation in line with the target allocations specified above, the assets are re-allocated or rebalanced regularly within each asset class. Because of the illiquid nature of private equity and real estate investments, it is not anticipated that these asset classes will be rebalanced on a regular basis. As of June 30, 2016, Cincinnati Children's made \$106,400 in funding commitments in nine investment partnerships of which \$59,223 had been funded. Additionally, Cincinnati Children's had made \$62,500 in funding commitments in eight real estate investment partnerships of which \$32,724 had been funded. It is anticipated that these commitments will be funded from liquid investments in the plan and any required funding contributions.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

Cincinnati Children's defined benefit plan investment allocation at the actuarial measurement date of June 30, 2016 and 2015 by asset category is as follows:

	2016	2015
Cash and cash equivalents	4.1%	6.9%
Equity mutual funds and EFTs	8.1%	-
Bond mutual funds and EFTs	7.7%	8.8%
Common stock	1.5%	3.6%
Corporate bonds	8.1%	5.4%
Government bonds	0.6%	0.1%
Investment Partnerships:		
Equity	14.8%	16.9%
Bond	15.7%	16.2%
International equity	35.7%	39.1%
Real estate	3.7%	3.0%
	100.0%	100.0%

At June 30, 2016, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 1(n) for further discussion on the fair value hierarchy and fair value principles):

	Level 1	Level 2	Level 3
Cash and cash equivalents	\$ 35,914	\$ -	\$ -
Equity mutual funds and EFTs	72,000		
Bond mutual funds and EFTs	67,964	-	-
Corporate bonds	-	71,713	-
Common stock	13,642	-	-
Government bonds	-	5,097	-
Investment Partnerships:			
Equity	-	97,296	33,660
Bond	-	138,628	-
International equity	-	315,273	-
Real Estate			32,811
	\$189,520	\$628,007	\$66,471

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

At June 30, 2015, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 1(n) for further discussion on the fair value hierarchy and fair value principles):

	Level 1	Level 2	Level 3
Cash and cash equivalents	\$ 60,197	\$-	\$ -
Equity mutual funds	16,000		
Bond mutual funds	76,137	-	-
Common stock	15,645	-	-
Corporate bonds	-	47,119	-
Government bonds	-	590	-
Investment Partnerships:			
Equity	-	121,794	24,883
Bond	-	141,049	-
International equity	-	340,894	-
Real estate	<u> </u>	<u>-</u>	25,513
	\$167,979	\$651,446	\$50,396

The fair values of Level 1 investments are based on quoted prices in active markets. The Level 2 and Level 3 investments in private investment funds are valued using the net asset value reported by the managers of the funds and as supported by the unit prices of actual purchase and sale transactions. The Level 3 investments in investment partnerships generally are associated with liquidation restrictions that may range from 91 days to the life of the fund (up to fifteen years) and may require redemption penalties.

Balance at July 1, 2015	\$ 50,396
Purchases	18,094
Unrealized gains	4,153
Sales	(6,172)
Balance at June 30, 2016	\$66,471
The amount of total gains or losses for the period included in changes in net assets attributable to the change in unrealized gains or losses related to assets still held at June 30, 2016	\$ 4,153

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

Balance at July 1, 2014	\$ 59,451
Purchases	20,110
Unrealized gains	6,779
Transfers	(30,117)
Sales	(5,827)
Balance at June 30, 2015	\$ 50,396
The amount of total gains or losses for the period included in changes in net assets attributable to the change in unrealized gains or losses related to assets still held at June 30, 2015	\$ 6,779

There were no transfers between levels in fiscal 2016. In fiscal 2015, there was one limited partnership bond fund that transferred from level 3 to level 2. In 2014, it was classified as level 3 due to certain redemption restrictions. In 2015, those restrictions expired and therefore, the limited partnership bond fund of \$30,117 was transferred from level 3 to level 2.

The following table reflects the weighted average assumptions utilized to determine benefit obligations:

	2016	2015
Discount rate used to determine actuarial present value of the		
projected benefit obligation	3.58%	4.43%
Assumed rate of increase in compensation levels	3.50%	3.50%
Long-term rate of return	7.00%	7.50%

Consolidated Financial Statements

For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

The following table sets forth the funded status of the plan and amounts recognized in the accompanying Consolidated Balance Sheets as of June 30, 2016 and 2015, utilizing actuarial measurement dates as of June 30, 2016 and 2015.

	2016	2015
Change in projected benefit obligation:		
Projected benefit obligation at beginning of year	\$1,099,073	\$ 999,568
Service cost	47,591	44,737
Interest cost	47,869	42,560
Other actuarial losses	165,872	42,486
Benefits paid	(54,711)	(30,278)
Projected benefit obligation at end of year	1,305,693	1,099,073
Change in plan assets:		
Fair value of plan assets at beginning of year	869,821	855,211
Actual loss on plan assets	(1,112)	(1,612)
Employer contributions	70,000	46,500
Benefits paid	(54,711)	(30,278)
Fair value of plan assets at end of year	883,998	869,821
Funded status	(421,695)	(229,252)
Net accrued pension liability in Consolidated Balance Sheets	\$(421,695)	\$(229,252)

In 2016 and 2015, the mortality tables utilized by actuaries to value the pension liability were updated based on current experience. The impact of the change in mortality assumptions is included in other actuarial losses in fiscal years 2016 and 2015.

Amounts included in Unrestricted Net Assets but not yet recognized in pension cost consist of:

	2016	2015
Net actuarial loss	\$688,555	\$481,056
Net prior service credit	(135,796)	(147,548)
	\$552,758	\$333,508

The estimated actuarial loss and prior service credit that will be amortized from Unrestricted Net Assets into net pension cost in fiscal 2017 are \$36,566 and \$(11,751) respectively.

The table below reflects the following weighted average assumptions utilized to determine benefit costs were:

	2016	2015
Discount rate used to determine actuarial present value of the		
projected benefit obligation	4.43%	4.31%
Assumed rate of increase in compensation levels	3.50%	4.00%
Expected long-term rate of return on plan assets	7.50%	7.50%

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

The Cincinnati Children's expected long-term rate of return on plan assets is based on the expected average returns based on the portfolio mix of plan assets and is reassessed on an annual basis.

Net periodic pension cost for 2016 and 2015 related to the defined benefit plan consisted of the following components:

	2016	2015
Service cost	\$47,591	\$44,737
Interest cost	47,869	42,560
Return on plan assets	(65,876)	(60,619)
Amortization of prior service credit	(11,751)	(11,751)
Recognized net actuarial loss	25,361	24,790
Net periodic pension cost	\$43,194	\$39,717

Based on preliminary estimates, we do not expect any required fiscal 2017 contributions for the qualified defined benefit plan under the current funding regulations.

The accumulated benefit obligation for the pension plan was \$1,273,156 and \$1,080,717 at June 30, 2016 and 2015, respectively.

Cincinnati Children's estimated benefit payments in each of the next five fiscal years and in aggregate for the five fiscal years thereafter are as follows:

2017	\$ 76,228
2018	76,225
2019	77,458
2020	79,443
2021	81,158
2022-2026	425,746

All other retirement plans maintained by Cincinnati Children's are defined contribution plans. Cincinnati Children's contributions to these plans are generally based on ten percent of salaries up to established ERISA limits. Total expense related to these other plans was approximately \$22,143 and \$21,767 in fiscal 2016 and 2015, respectively.

Cincinnati Children's has a nonqualified deferred compensation plan, which permits eligible officers, directors and key employees to defer a portion of their compensation. The deferred compensation amounts are in participant directed investments. The participants have the option of deferring the amounts for no less than two years, but no greater than retirement age. If a participant chooses to defer amounts to less than retirement age they have one option to extend the deferral term or to be paid out the fair value of the assets, net of taxes upon expiration. The amounts are at a substantial risk of forfeiture and will revert back to the Cincinnati Children's if the employee is not actively employed at the vesting date. The fair value of the assets and liabilities to participants included in the accompanying Consolidated Balance Sheets were \$8,446 and \$11,296 at June 30, 2016 and 2015, respectively. The amount of deferred compensation income recognized in fiscal 2016 was \$232 and deferred compensation expense recognized in fiscal 2015 was and \$1,090. Additionally, Cincinnati Children's provides for individual nonqualified deferred compensation benefits for retention of key employees with varying terms. The fair value of the assets and liabilities to participants are and easily agreements in the accompanying Consolidated Balance Sheets were \$7,211 and \$7,466, respectively at June 30, 2016 and 2015.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

In addition to providing pension benefits, Cincinnati Children's makes available medical and dental benefits for certain eligible employees upon retirement from the Cincinnati Children's at cost. Substantially all employees may become eligible for such benefits upon retiring from active employment of the Medical Center. Former employees who retired prior to March 1, 1997 are entitled to subsidized medical and dental benefits.

The postretirement benefit obligations, included within other long-term liabilities, as of June 30, 2016 and 2015 were as follows:

	2016	2015
Change in benefit obligation:		
Benefit obligation at beginning of year	\$3,659	\$3,769
Interest cost	112	105
Plan participants contributions	39	111
Plan amendment	(134)	-
Actuarial (gain) loss	(45)	321
Benefits paid	(473)	(647)
Benefit obligation at end of year	\$3,158	\$3,659

Amounts included in Unrestricted Net Assets but not yet recognized in postretirement cost consist of:

	2016	2015
Net actuarial loss	\$ 3,202	\$ 3,625
Net prior service cost	(2,460)	(3,003)
	\$ 742	\$ 622

The estimated actuarial loss and prior service credit which will be amortized from Unrestricted Net Assets into net postretirement cost in fiscal 2017 are \$357 and \$(582), respectively.

The above table reflects the following weighted average assumptions to determine postretirement obligations:

	2016	2015
Discount rate	2.47%	3.27%
Health care cost trend rate	5.00%	5.00%

Net periodic cost for 2016 and 2015 related to the medical and dental postretirement benefits consisted of the following components:

	2016	2015
Interest cost	\$112	\$ 105
Amortization of unrecognized net gain and prior service credit	(300)	(319)
	\$(188)	\$(214)

For fiscal 2016 and fiscal 2015, the discount rate used to determine the net periodic postretirement costs was 3.27% and 3.00%, respectively.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

Assumed healthcare cost trend rates have a significant effect on the amounts reported for healthcare plans. A one-percentage-point change in assumed healthcare cost trend rates would have the following effects:

	1-Percentage- Point <u>Increase</u>	1-Percentage-	
		Point Decrease	
Effect on total of service and interest cost components	\$763	\$(688)	
Effect on accumulated postretirement benefit obligation	-	-	

Cincinnati Children's expects to make the future benefit payments, which reflect expected future service, as appropriate. The following benefit payments are expected to be paid over each of the next five years and thereafter.

	Payments
2017	\$ 393
2018	365
2019	337
2020	310
2021	284
2022-2026	1,056

(9) Commitments and Contingencies-

- (a) <u>Litigation</u>-- Cincinnati Children's is engaged from time to time in a variety of litigation and regulatory compliance matters in addition to professional and general liability matters. Management assesses the probable outcome of unresolved litigation and records estimated reserves consistent with ASC No. 450, "Contingencies". After consultation with legal counsel, management believes that all such currently existing matters will be resolved without material adverse impact to the consolidated financial position or results of operations of Cincinnati Children's.
- (b) <u>Laws and Regulations</u>--The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. Compliance with these laws and regulations, specifically those relating to the Medicare and Medicaid programs, can be subject to review and interpretation, as well as regulatory actions unknown or unasserted at this time. Federal and State government activity continues with respect to investigations and allegations concerning possible violations of regulations by health care providers, which could result in the imposition of significant fines and penalties, as well as significant repayment of previously billed and collected revenue from patient services. Management believes that the Cincinnati Children's is in compliance, in all material respects, with fraud and abuse as well as other applicable government laws and regulations. Cincinnati Children's has recorded reserves for routine regulatory compliance issues and believes these reserves are adequate to cover any potential repayment of previously billed and collected revenue from patient services.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

- (c) <u>Capital Commitments</u>—Cincinnati Children's has entered into agreements with general contractors for several new construction projects, renovation projects, equipment and information system technology projects. The Medical Center has committed to spend an additional approximately \$41,567 in connection with current active projects as of June 30, 2016. The projects are expected to be completed in fiscal 2017 and fiscal 2018.
- (d) <u>Funding Commitments</u> -- During fiscal 2005, the Board of Trustees of Cincinnati Children's approved a revocable commitment for up to a \$15,000 non-recourse loan over seven years to Uptown Consortium Inc. These funds are to be used to invest in commercial and residential projects in the uptown area. As of June 30, 2016, Cincinnati Children's has provided \$12,867 of funding in relation to this commitment, and management does not anticipate any additional funding.

During fiscal 2016, the Board of Trustees of Cincinnati Children's approved a revocable commitment for up to a \$5,000 non-recourse loan over ten years to Uptown Consortium Inc. These funds are to be used to invest in commercial and residential projects in the uptown area. As of June 30, 2016, Cincinnati Children's has provided \$3,861 of funding in relation to this commitment.

(e) <u>Investment Commitments</u> – Cincinnati Children's has made commitments to invest \$12,000 in two limited partnerships that focus on investing in venture capital funds or provide venture capital for companies in the high-growth sectors of the economy, including life sciences, information technology and advanced manufacturing. As of June 30, 2016 and 2015, Cincinnati Children's had funded \$10,376 and \$10,072, respectively, of this commitment. At June 30, 2016 and 2015, respectively, the value of the investment recorded in Other Assets in the Consolidated Balance Sheets is \$8,349 and \$9,096. Distributions from the limited partnership are made at the discretion of the General Partner, primarily based on distributions from investee partnerships and sales of securities less partnership agreement. Redemptions of partnership interests prior to termination of the partnership defined in the limited partnership agreement are not anticipated.

Cincinnati Children's has made a commitment to invest \$5,000 in a limited partnership that focuses on investing in venture capital funds or provides ventures capital for companies in the high growth sectors of the economy, including life sciences, information technology and advanced manufacturing. As of June 30, 2016 and 2015, Cincinnati Children's has funded \$4,113 and \$3,100 of this commitment. At June 30, 2016 and 2015, the value of the investment recorded in Other Assets in the Consolidated Balance Sheets is \$3,965 and \$3,372, respectively. Distributions from the limited partnership are made at the discretion of the General Partner, primarily based on distributions from investee partnerships and sales of securities less partnership expenses and amounts retained for working capital, as provided for in the limited partnership agreement. Redemptions of partnership interests prior to termination of the partnership defined in the limited partnership agreement are not anticipated.

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

Cincinnati Children's has made a commitment to invest \$5,000 in a limited liability corporation (LLC) that focuses on investing in early stage venture capital funds regionally and nationally. The goal is to make the Cincinnati region the place for entrepreneurs and investors to launch new ideas. As of June 30, 2016 and 2015, Cincinnati Children's had funded \$1,774 and \$945, respectively, of the commitment. At June 30, 2016 and 2015 the value of the investment recorded in Other Assets in the Consolidated Balance Sheets is \$1,899 and \$886, respectively. Unless the LLC is dissolved earlier in accordance with defined termination provisions, the term of the LLC shall end on the 12th anniversary of the date of the last sale of membership interests, subject to extension in the three one-year increments with written notice. In general, no member shall have the right to withdraw from the LLC.

Cincinnati Children's has made a commitment to invest \$3,000 in a limited partnership that invests primarily in high growth Information Technology and healthcare companies that leverage technology to make their customers' business or products/services better, faster or less expensive. As of June 30, 2016 and 2015, Cincinnati Children's has funded \$1,860 and \$1,260, respectively, of this commitment. At June 30, 2016 and 2015, the value of the investment recorded in Other Assets in the Consolidated Balance Sheets is \$1,944 and \$1,099, respectively. Distributions from the limited partnership are made at the discretion of the General Partner, primarily based on distributions from investee partnerships and sales of securities less partnership expenses and amounts retained for working capital, as provided by in the limited partnership agreement. Redemptions of partnership interests prior to termination of the partnership defined in the limited partnership agreement are not anticipated.

Cincinnati Children's has made an a commitment to invest \$2,100 in five limited liability corporations (LLC's) whose purpose is private-public seed-stage investor whose mission is to strengthen the regional economy by driving talent and capital into scalable technology companies in southwest Ohio. At June 30, 2016 and 2015, Cincinnati Children's has funded \$1,260 and \$1,003, respectively, of this commitment. At June 30, 2016 and 2015, respectively, the value of the investment recorded in Other Assets in the Consolidated Balance Sheets is \$1,604 and \$1,352, respectively. Unless the LLC is dissolved earlier in accordance with defined termination provisions, the term of the LLC shall end on the 12th anniversary of the date of the last sale of membership interests, subject to extension in the three one-year increments with written notice. In general, no member shall have the right to withdraw from the LLC.

(f) <u>Operating Leases</u> – Cincinnati Children's leases certain property for varying periods. Rent expense related to such leases was approximately \$5,300 and \$5,600 in fiscal 2016 and 2015, respectively. Future minimum rental commitments under non-cancellable operating leases are as follows:

FY 2017	\$5,390
FY 2018	2,057
FY 2019	1,211
FY 2020	825
FY 2021	463
Thereafter	247

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements For the Years Ended June 30, 2016 and 2015, respectively (dollars in thousands)

(10) Functional Expenses-

The functional expenses of Cincinnati Children's are as follows:

	2016	2015
Patient services	\$1,347,050	\$1,305,525
Physician services, research and education	507,630	453,745
Support services	242,471	237,576
	\$2,097,151	\$1,996,846

(11) Fair Value of Financial Instruments-

The following methods and assumptions were used by Cincinnati Children's in estimating its fair value disclosures for financial instruments:

<u>Cash and Cash Equivalents</u>--The carrying amounts reported in the Consolidated Balance Sheets approximate fair value.

<u>Accounts Receivable and Accounts Payable</u> -- The carrying amounts reported in the Consolidated Balance Sheets approximate fair value because of the relative short maturity of these items.

<u>Marketable Securities and Assets Limited As To Use</u>--The carrying amounts reported in the Consolidated Balance Sheets approximate fair value. Management, with the assistance from the trustee holding the asset, determined the fair value based on published market prices.

<u>Bonds Payable and Notes Payable</u>--The fair values of Cincinnati Children's 's bonds payable and notes payable are estimated by management, with assistance from a third party, based on current rates for debt with similar remaining maturities. The fair value of the bonds payable at June 30, 2016 and 2015 was \$771,275 and \$747,948, respectively. These would be classified as Level 2 investments in the fair value hierarchy.

(12) Subsequent Events-

Management reviewed subsequent events through October 17, 2016, the date the consolidated financial statements were issued, noting no changes were required to the consolidated financial statements or footnotes, except for the following as to which the date is January 27, 2017. Subsequent to year-end, Cincinnati Children's issued the 2016X tax-exempt bonds in the amount of \$51,690 to refund the 2006K tax-exempt bonds and issued the 2016Y taxable bonds in the amount of \$100,000. The 2016X bonds bear interest at 2.780% to 3.03% through 2032 and the 2016Y bonds bear interest at 2.853% through 2026.

Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
Department of Defense	Military Medical Research and Development	Identification of molecular and cellular contributors to				W81XWH1210133	12.420	\$ - 9	s 403,480 \$	403,480
		Targeting the Ron-DEK Signaling Axis in Breast Cancer				W81XWH1210194	12.420	0	4,594	4,594
		Regulation of Intracellular Trafficking in NF2				W81XWH1310136	12.420	0	181,636	181,636
		Prenatal Antidepressants and Autism Spectrum Disorder				W81XWH1310306	12.420	0	8,624	8,624
		Development of Somatic Cell Therapy for Infection-induce				W81XWH1310437	12.420	0	5,481	5,481
		Investigating the Mechanisms of Leukemia Initiation in				W81XWH1510344	12.420	0	162,706	162,706
		Mechanisms of nonalcoholic steatohepatitis				W81XWH1510370	12.420	0	153,205	153,205
		IL-9-Producing Mast Cell Precursors and Food Allergy				W81XWH1510517	12.420	0	263,391	263,391
		Modelling and Targeting of Oncogenic Liability in Drug-R				W81XWH1610028	12.420	0	39,568	39,568
		NF Consortium Infrastructure and Trial#1: "Open-label,	University of Alabama-Birmingham	0004222088-003		W81XWH1210155	12.420	0	36,133	36,133
		A Phase II Trial on the Effect of Low-Dose versus High-D	University of Utah	10025577-03		W81XWH1210487	12.420	0	12,115	12,115
		Induction of Food Allergy in Mice by Allergen Inhalation	Cincinnati Educ & Res for Veterans	00100		W81XWH1310497	12.420	0	129,818	129,818
		Global Mapping of Antimicrobial Resistance	Georgetown University	411401 GR411256-CHMC		W81XWH15C0170	12.420	0	15,483	15,483
					Military Medical Research and Developme	nt Total		0	1,416,235	1,416,235
	Research and Technology Development	Uncovering general principles of network dynamic of circ	University of Cincinnati	007919-024		D12AP00005	12.910	0	64,309	64,309
					Research and Technology Development T	otal	-	0	64,309	64,309
	Community Economic Adjustment Diversification Planning	A Randomized, Placebo-Controlled Trial of D-Cycloserine	Indiana University Health	6029		W81XWYH0910091	12.614	0	57 448	57 448
	Community Economic Adjustment Diversification Planning	A Randomized, Placebo-Controlled That of D-Cyclosenne	Indiana University Realth	6029	Community Economic Adjustment Diversi		12.014	0	57,448	57,448
					Community Economic Adjustment Diversi	incation Planning Total		U	57,440	57,440
	Research on Chemical and Biological Defense	Dose-Finding Study of Lyophilized Shigella sonnei 53G				W911QY1620002	12.360	0	39,627	39,627
					Research on Chemical and Biological Defe	ense Total	-	0	39,627	39,627
					Department of Defense Total		-	0	1.577.618	1.577.618
									1. 1.	
Department of Education	National Institute on Disability and Rehabilitation Research	SPAN - A Tool for Social Participation And Navigation				H133G130272	84.133	0	(172,330)	(172,330)
		Rehabilitation Research and training Center for Traumati			Case Western Reserve University	H133B090010	84.133	18,746	(30,462)	(8,633)
					Research Inst. at Nationwide Hos		_	3,083	0	0
					National Institute on Disability and Rehabi	litation Research Total	-	21,829	(202,792)	(180,963)
	Special Education-Grants for Infants and Families	HMG Hospital Based Regional Child Find - Jaeger	Ohio Department of Health	03130011HB0815		03130011HB0815	84.181	0	8 876	8.876
	opeoial Education-oranis for infants and ramines	nino nospital based regional onlid find - baeger	Onio Department of Fleater	001000111100010	Special Education-Grants for Infants and I		-	0	8,876	8,876
					· · · · · · · · · · · · · · · · · · ·		-			(150.005)
					Department of Education Total			21,829	(193,916)	(172,087)
Department of Justice	Crime Victim Assistance	VOCA 2013	Crime Victims Assistance Office	2017-VOCA-43552065		R2013VADSCE483	16.575	0	130,979	130,979
					Crime Victim Assistance Total		-	0	130,979	130,979
									,	,
	Improving Investig & Prosecution of Child Abuse & Reg & Local Children's Advocacy	State Chapter Support to Children's Advocacy Centers	National Children's Alliance	07-CINC-OH-SA16		07-CINC-OH-SA16	16.758	0	9,000	9.000
	······································	,			Impr. Investig. & Prosecu. of Child Abuse		-	0	9,000	9,000
					impri inteedig: a treesedii er enina Abaee			•	0,000	0,000
	Crime Victim Assistance/Discretionary Grants	National Crime Victim's Right Week Community Awareness	Crime Victims Assistance Office	16-050		2015-VF-GX-K002	16.582	0	4.550	4.550
	onno visini rissistanos sistentiary oranto	Halonal onno Holmo Hight Hook commany Analonoo		10 000	Crime Victim Assistance/Discretionary Gr		10.002	0	4,550	4,550
					onne victim Assistance/Discretionary of			0	4,000	4,000
					Department of Justice Total		-	0	144,529	144,529
Department of Agriculture	Agriculture and Food Research Initiative (AFRI)	Inactivation of enteric foodborne viruses in high risk				2011-680033005	10.310	0	98.669	98.669
Doparation: of Agricalato	rightana ana roba ritobanan mitatro (ritra)	Universal Flu Vaccine by a Norovirus P Particle Platform	The Ohio State University	60033189		2013-6701520476	10.310	ů	170,025	170,025
		onversar na vacene by a norovirus n nancie nationn	The Onio Otale Oniversity	00000100	Agriculture and Food Research Initiative (10.010	0	268,694	268.694
					Agriculture and Food Research Initiative (AFRI) Iotai		U	200,094	200,094
					Department of Agriculture Total		-	0	268,694	268,694
Dept of Health and Human Serv	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	SPAN - A Tool for Social Participation And Navigation			Georgia Tech Research Corporation	90IF0059-01-00	93.433	39,035	292,474	345,842
		Databilitation Dessent and Training for Terror die Desig			University of Wisconsin System	90RT5004-01-00	93.433	14,333 15.344	0	0
		Rehabilitation Research and Training for Traumatic Brain			Case Western Reserve University ACL National Inst. on Disability, Independ		93.433	68,713	329,517 621,990	344,861 690,703
						-				
	Affordable Care Act (ACA) Primary Care Residency Expansion Program	Expansion of a Pediatric Primary Care Resident Training			Affordable Care Act (ACA) Primary Care R	HP20766	93.510	0	481,607 481.607	481,607 481.607
					Anordable care Act (ACA) Frimary Care R	concercy Expansion Program Total		U	401,007	401,007
	Aging Research	Homeostasis and function of regulatory T cells in aging			University of Cincinnati	AG033057	93.866	14,511	391,983	406,494
		Lineage Determination and Tissue HomeOstasis in the Aged				AG040118	93.866	0	326,019	326,019
		Premature Uterine Aging and Preterm Delivery				AG040858	93.866	0	10,519	10,519
		Stem cell aging and biomarker studies				AG050650	93.866	0	534,581	534,581
		Hypoxia Signaling and Spontaneous Pulmonary Fibrosis in	University of South Florida	6145-1029-00-A		AG047473	93.866	0	61,135	61,135
					Aging Research Total		_	14,511	1,324,237	1,338,748
					• • · · · · · · · · · · · · · · · · · ·					,,· ···

See Notes to Schedule of Expenditures of Federal Awards.

Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total E
	Allergy, Immunology and Transplantation Research	Clinical Immunization Safety Assessment				200-2012-53661	93.855	0	44,140	
		Potential Mechanisms for Intussusception after Rotavirus				200-2012-53661	93.855	0	237,268	:
		Clinical Study of the Safety of Quadrivalent Live Attenu				200-2012-53661	93.855	0	28,377	
		Clinical Study of Simultaneous Administration of Tetanus				200-2012-53661	93.855	0	18,123	
		Genetic Linkage in Lupus				AI024717	93.855	0	45,330	
		Regulation of Gastrointestinal Eosinophils				AI045898	93.855	0	392,663	
		Regulation of Apoptosis in Activated Primary T Cells				AI057753	93.855	0	33,261	
		Epithelial Genes in Allergic Inflammation			Johns Hopkins University	AI070235	93.855	516,038	979,377	1
		Role of Viral Chemokine Receptors in Cytomegalovirus Lat			University of Queensland	AI087683	93.855	50,570	152,705	
		Regulatory T cells dictate immunity during persistent Sa			,	AI087830	93.855	0	(10,498)	
		Explaining Racial Disparities in Child Asthma Morbidity				AI088116	93.855	0	715	
		Novel Vaccine Against Norovirus			Virginia Tech	AI089634	93.855	13,269	264,701	
		Regulation of TH2 memory/effector cells during allergic			-	AI090129	93.855	0	40,485	
		HSV latency and reactivation and the novel neuronal regu			University of Cincinnati	AI093614	93.855	113,387	286,946	
		,			Van Andel Institute			107,387	0	
		Role of Spi-C in eosinophil development and functional				AI093673	93.855	0	59,178	
		The immune pathogenesis of prenatal listeria monocytogen				AI100934	93.855	0	319,642	
		DNA methylation in children hospitalized with asthma exa				AI101375	93.855	0	(53,821)	
		Regulation of Adult Stem Cell Homeostatic Response to In				AI103388	93.855	0	55,513	
		Molecular Mechanism of Eosinophil Cell Death				AI103853	93.855	0	140,059	
		Epidemiologic Impact of HPV Vaccination			Indiana University	AI104709	93.855	81,948	434,002	
					University of California			20.390	0	
		cGMP Metabolism in Resistance to Bacterial Infection				AI107274	93.855	0	14,678	
		Exploiting the DNA damage response to selectively sculpt				AI109810	93,855	0	368,408	
		CD4 T cells with specificity to noninherited maternal an				AI112186	93.855	0	180,702	
		Food Allergy and Goblet Cell Antigen Passages			Washington University	AI112626	93.855	42,257	634.038	
		Inpatient Asthma Care for Children: Adding a Place-Based			··	AI112916	93.855	0	118,451	
		Consortium of Eosinophilic Gastrointestinal Disease Rese			Children's Hospital of Philadelphia	AI117804	93.855	87,818	455,866	
					Indiana University			44.815	0	
					Northwestern University			103,205	0	
					Tufts Medical Center, Inc			27.303	0	
					University of California			64,385	ő	
					University of Colorado			70,245	0	
					University of North Carolina-Chapel Hill			44,473	0	
		A follicular regulatory subset of natural killer cells			chinology of North Carolina Chapor him	AI118179	93.855	0	37,439	
		Lipoxins and control of inflammation during cerebral mal				AI118302	93.855	0	211.174	
		Maternal Regulatory T cell antigen-specificity				AI120202	93.855	0	53,249	
		Biomarkers and Risk Stratification in Pediatric Communit				AI121325	93.855	0	52,939	
		Human monoclonal antibodies against norovirus.				AI122132	93.855	ő	32,066	
		Systemic immune modulation by enteric commensal fungi.				AI122132 AI123089	93.855	0	8.757	
		Genetic and Immunological Dissection of Eosinophilic Eso				AI124355	93.855	0	343,147	
		Vaccine and Treatment Evaluation Units (VTEUs)				HHSN272200800006C	93.855	0	2,718,937	
		Vaccine and Treatment Evaluation Units (VTEU).				HHSN272201300016I	93.855	0	874,995	
		Analysis of Staphylococcus Aureus Host Interactions	Texas A & M	23-S132304		AI020624	93.855	0	22,652	
		Immunology/Allergy Fellowship Training Grant	University of Cincinnati	1012740		AI060515	93.855	0	112.245	
		Immunobiology of Peanut Allergy and its Treatment: A Pro	Icahn School of Medicine at Mount Sinai	0254-6980-4609		A1066738	93.855	0	(130)	
		B-Cell Targeted Induction to Improve Outcomes in Pediatr	Washington University	WU-16-330		AI077810	93.855	0	115,587	
		Gene Therapy for SCID-X1 Using Self-Inactivating Gammare	Children's Hospital Boston	RSTFD0000593886		AI077810 AI087628	93.855	0	9,502	
		Prospective Cohort Study of Severe Bronchiolitis and Ris	Massachusetts General Hospital	219473		Al087881	93.855	0	3,001	
				219475 7147sc			93.855	0	116,748	
		Immunosuppression Withdrawal for Stable Pediatric Liver	University of California University of Cincinnati	008098		AI100807 AI103816	93.855	0	4,863	
		Human IgG-Mediated Anaphylaxis	Stanford University	60837668-107582		AI103818 AI104342	93.855	0	52,824	
		Biomarkers for Post-Transplant Lymphoproliferative Disor GM-CSF-Induced Metal Sequestration and Histoplasma	University of Cincinnati	1010447		Al104342 Al106269	93.855	0	52,824 30.096	
			University of Cincinnati University of Cincinnati	008966-004		AI106269 AI111062	93.855	0	30,096	
		Translational repression and Aspergillus fumigatus virul						0		
		Suppression of IgE-Mediated Disease by Polyclonal Rapid	University of Cincinnati	1011228		AI113162	93.855	0	86,419	
		Inner City Asthma Consortium 3	University of Wisconsin-Madison	561K341		AI114271	93.855	0	644,676	
		Infant specific-IgE, rhinovirus-C bronchiolitis, and inc	Massachusetts General Hospital	225488		AI114552	93.855	0	12,194	
		EpigeneticProgramming of Innate Immunity in Pediatric	U.C. Davis Medical Center	201501947-01		AI116129	93.855	0	8,504	
		Revealing networks targeted by HSV-1 ncRNAs with in vivo	University of Cincinnati	1011619		AI116389	93.855	0	53,244	
		Intestinal Organoids as a model system for studying ente	University of Cincinnati	1012441/1012440		Al116491	93.855	0	609,808	
		Microwave-Accelerated Metal-Enhanced Fluorescence	University of Maryland (College Park)	0000016499		AI117272	93.855	0	15,936	
					Allergy, Immunology and Transplantation			1.387.488	11.482.892	

See Notes to Schedule of Expenditures of Federal Awards.

Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
	Arthritis, Musculoskeletal and Skin Diseases Research	Molecular Mechanisms of Myotonic Dystrophy				AR044387	93.846	0	(215)	(215)
		Cincinnati Rheumatic Disease Core Center			Case Western Reserve University	AR047363	93.846	26,853	654,494	691,120
		Multidisciplinary Clinical Research Center			Stanford University Arkansas Children's Hospital	AR047784	93.846	9,773 4,356	0 (3,583)	0 7,827
		Multuiscipinary cinicar Research Center			Connecticut Childrens Medical Center	AI(047764	55.040	2,496	(3,383)	0
					Emory University			744	0	0
					Medical College of Wisconsin Phoenix Children's Hospital			1,504 2,310	0	0
		Gene Expression In Pediatric Arthritis			Arkansas Children's Hospital	AR048929	93.846	1,840	1,033,718	1,301,603
					Carolinas Healthcare System			19,330	0	0
					Children's Hospital Boston Children's Mercy Hospital			3,080 6,398	0	0
					Emory University			2,506	0	0
					Indiana University			4,325	0	0
					Medical College of Wisconsin University of Cincinnati			1,434 162,630	0	0
					University of Pittsburgh			6,892	0	0
					Wake Forest Univ School of Medicine			59,451	0	0
		Myotonic Dystrophy type 2 Longitudinal Determination of Outcomes of Adolescents wi				AR052791 AR054842	93.846 93.846	0	316,050 (4,128)	316,050 (4,128)
		Behavioral Interventions and Long Term Outcomes in Juven				AR056687	93.846	0	(4, 128) 171,224	(4, 128) 171,224
		Enhancing PROMIS in Pediatric Pain, Rheumatology, and Re				AR057940	93.846	0	(184)	(184)
		MUNC13-4 gene Polymorphisms in Macrophage Activation				AR059049	93.846	0	355,086	355,086
		The Role Of IL-31 In TH2 Cytokine-Driven Systemic Sclero Fibromyalgia Integrative Training Program for Teens (FIT				AR062832 AR063412	93.846 93.846	0	47,766 39,385	47,766 39,385
		Regulated Morphogenesis of Human Sebaceous Glands				AR064341	93.846	Ő	(526)	(526)
		Inhibition of GSK3 beta as potential therapy for DM1			University of Cincinnati	AR064488	93.846	33,082	177,312	210,394
		Mechanisms of Muscle Afferent Sensitization after Ischem Identification of Patellofemoral Pain Risk Factors Devel				AR064551 AR065068	93.846 93.846	0	373,408 213,497	373,408 213,497
		Innovative Efficacy Measures of Lupus Nephritis Therapie			Ann & Robert H Lurie Children's Hosp.	AR065098	93.846	7,250	115,399	161,296
					The Ohio State University			18,451	0	0
		Optimization of Outcome Measures For Clinical Trials in			University of Cincinnati University of Cincinnati	AR067166	93.846	20,196 49,542	0 93.820	0 143.362
		Randomized Clinical Trial of FIT Teens for Juvenile Fibr			Children's Mercy Hospital	AR067978	93.846	7,322	193,482	274,947
					Connecticut Childrens Medical Center			29,728	0	0
					Research Inst. at Nationwide Hos The Ohio State University			21,204 4,792	0	0
					University of Louisville			18,420	0	0
		Cincinnati Center for Innovative Medicine in Adult & Ped				AR067692	93.846	0	67,076	67,076
		Real-Time Sensorimotor Feedback for Injury Prevention As Deciphering mechanisms of myoblast fusion				AR067997 AR068286	93.846 93.846	0	13,350 325,009	13,350 325,009
		Multi-faceted Approach Modeling ACL Injury Mechanisms	The Ohio State University	60041067		AR056259	93.846	0	1,995	1,995
		A Developmentally-Based Tissue Engineering Approach to	University of Cincinnati	006211		AR056943	93.846	0	(499)	(499)
		Prospective Study of Bio-mechanics and Early Degeneratio Distinct functional Outcomes of BCR/TLR7 and BCR/TLR9	The Ohio State University University of Massachusetts	60041378 WA0043657/RFS2015154		AR064923 AR066808	93.846 93.846	0	94,731 89,538	94,731 89,538
		PEARL: Pathway Exploration and Analysis in Renal Lupus	Feinstein Institute for Medical Research	500678CHMC		AR067688	93.846	0	44,161	44,161
					Arthritis, Musculoskeletal and Skin Diseas	es Research Total		525,907	4,411,366	4,937,273
	Assistance Programs for Chronic Disease Prevention and Control	SEARCH for Diabetes in Youth, Phase 3: Registry Study -				DP002709	93.945	0	139,881	139,881
	Assistance Programs for Chronic Disease Prevention and Control	SEARCH for Diabetes in Youth, Fridse 3. Registry Study - SEARCH for Diabetes in Youth Registry Study, Phase 4: Oh				DP006134	93.945	0	236,293	236,293
					Assistance Programs for Chronic Disease	Prevention and Control Total		0	376,173	376,173
	Biomedical Research and Research Training	Biochemical and Genetic Analysis of Notch Signaling				GM055479	93.859	0	(4.145)	(4,145)
	5	Regulation of Wingless (Wg) Signaling and Morphogen Grad				GM063891	93.859	0	199,919	199,919
		PPARgamma and PPARgamma Agonists in Septic Shock Hox Control of Cell-Specific EGF Signaling During Develo			Medical University South Carolina	GM067202 GM079428	93.859 93.859	45,238	194,486 322,575	239,724 322,575
		Roles of Retromer Complex in Development				GM079428 GM087517	93.859	0	(2,643)	(2,643)
		Studies of metal-dependent intercellular adhesion in Sta				GM094363	93.859	0	184,819	184,819
		MMP-8 as a Novel Therapeutic Target in Sepsis DNA Damage Response Pathways in Mieotic Sex Chromosome I				GM096994 GM098605	93.859 93.859	0	(11,489) 137,559	(11,489) 137,559
		Novel Mechanisms of Regenerative Fetal Wound Repair by				GM098805 GM098831	93.859	0	137,559	137,559
		Stratification of pediatric septic shock			Baylor College of Medicine.	GM099773	93.859	4,500	420,691	452,891
					Children's Hosp & Clinics of Minnesota			3,000	0	0
					Children's Hospital Med Center of Akron Children's Hospital Oakland			8,700 4,000	0	0
									0	0
					CHOC Children's Hospital			8,000	0	0
					CHOC Children's Hospital Hackensack University Medical Center Indiana University			8,000 500 1,500	0	0

See Notes to Schedule of Expenditures of Federal Awards.

Gov Agency Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
	Regulation and Scaling of a Morphogen Gradient Organization of the inactive X-chromosome Molecular and Neural Mechanisms of Temperature Preferenc Novel diagnostic and stratification tools for septic sho novel signaling function of Cdc42 GTPase in vivo G-CSF in Human Severe Congenital Neutropenia Novel Mechanisms of Regenerative Wound Healing A genetic approach to defining the Ttc21b interactome in Molecular Regulation of Neutrophil Transcellular Migrati Age-dependent mechanisms of metabolic recovery in hemorr Molecular mechanisms regulating intestinal stem cell act Mouse and Guinea Pig Models for Herpesviruses T32 Training Grant Role of Eicosanoids in Shock Extracellular matrix remodeling and fibrosis Structure-Function Investigation of DAN-mediated BMP Ant	University of Cincinnati Medical University of South Carolina University of Rochester University of Cincinnati	1011193 MUSC12-086 416053-004-G 1011838	University of Cincinnati University of Pittsburgh Stanford University Biomedical Research and Research Trair	GM101373 GM102184 GM107582 GM108025 GM108025 GM110628 GM111028 GM112744 GM112792 GM115973 GM115973 GM115973 GM115973 GM127922010000081 GM002478 GM027673 GM097347 GM114640 https://doi.org/10.00000000000000000000000000000000000	93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859 93,859	0 0 59,516 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	198,947 278,445 270,406 505,115 0 226,939 310,854 (104) 302,052 328,901 274,088 284,046 592,593 9,600 33,856 50,065 35,075 5,152,697	198,947 278,445 270,406 632,219 0 256,939 310,854 716 302,052 328,901 274,088 284,046 592,593 9,600 33,856 50,065 35,075 5,358,059
Blood Diseases and Resources Research	Role of FA proteins in hematopoiesis TCD with Transfusions changing to Hydroxyurea TCD with Transfusions changing to Hydroxyurea Mechanisms Linking Hemostatic Factors to Neuroinflam Fanconi Anemia as a Model for Susceptibility to Human Patient-Provider Interventions to Improve Transition to Identification and characterization of genes in del(5q) The Role of MEIS1 in Hematopoiesis and Hematopoietic Hemostatic factors and sixtic cell disease Role of TRAF6 in Myelodysplastic Syndromes Rho GTPases in Terminal Erythroid Maturation Cinchnati Center of Excellence in Hemoglobinopathies Re Mechanisms of granulocyte homeostasis A Controlled Clinical Trial of Regadenoson in Sickle Cel PLOF-HIF1 and RAvis in Sickle Pulmonary Hypertension Endothelialized microfluidics for sickle cell disease r	Dana Farber Cancer Institute University of Southern California Emory University	1215303 H50996 T223869 TR43HL123103	Ann & Robert H Lurie Children's Hosp. Baylor College of Medicine. Case Western Reserve University Children's Hosp & Clinics of Minnesota Children's Hosp At Et Kings Daughters Children's Hospital Boston Children's Hospital Boston Children's Hospital of Philadelphia Children's Hospital of Philadelphia Children's Research Institute Columbia University Duke University Bast Carolina University Corolia Research Institute. Inc Medical University South Carolina Nemours Children's Clinic, Jacksonville Resch Found for State Univ of New York St Jude Children's Research Hospital State of Mississippi The Feinstein Institute Medical Research The Hospital for Sick Children University of South Alabama University of South Carolina University of South Carolina University of South Carolina University of South Carolina University of Texas Health Science Ctr University of South Carolina University of Careas Southwestern Wayne State University Cleveland Clinic Foundation University of Cincinnati University of Clinicinati	HL 103745 HL 1095647 HL 1095647 HL 1095647 HL 106672 HL 108102 HL 108720 HL 11103 HL 111203 HL 111203 HL 111203 HL 114582 HL 11709 HL 112261 HL 117709 HL 112261 HL 117709 HL 112261 HL 11772 HL 112261 HL 11772 HL 112261 HL 11772 HL 112261 HL 11772 HL 112261 HL 11261 HL 11261	93.839 93.839	0 2,790 31,615 22,004 1,589 4,169 4,00 12,134 4,169 4,00 12,134 5,167 700 80,406 114,562 10,417 4,950 17,260 114,562 2,514 5,612 15,142 3,531 4,828 2,74 2,920 412,186 6,663 2,4,052 11,563 2,4,052 11,563 2,4,052 11,563 2,4,052 11,563 2,4,052 11,563 2,4,052 11,563 2,4,052 11,563 2,4,052 11,563 2,6,059 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(214) (1,039,579) (1,039,579) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(214) (229,308) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

See Notes to Schedule of Expenditures of Federal Awards.

 Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
Cancer Biology Research	Role of Foxm1 in Lung Cancer Microenvironment	-		·	CA142724	93.396	0	(28,752)	(28,752)
	Targeting Cdc42 in Leukemia Stem Cells				CA150547	93.396	0	(2,462)	(2,462)
	MicroRNA in Acute Myeloid Leukemia				CA159845	93.396	0	250,270	250,270
	Role of Age in Liver Cancer				CA159942	93.396	0	435,470	435,470
	A Novel Epigenetic Circuit in Acute Leukemia				CA187276	93.396	0	167,368	167,368
	Exploiting proteotoxic stress in therapy-refractory HER2 Hemostatic Factors Drive Prostate Cancer Pathogenesis				CA193549 CA193678	93.396 93.396	0	329,973 30,301	329,973 30,301
	Coagulation factors as modifiers of the colon cancer mic				CA193678 CA204058	93.396	0	117,189	117.189
	Hypoxia and Potassium Channel Activity in T Lymphocytes	University of Cincinnati	1011985		CA204058 CA095286	93.396	0	7.040	7.040
	Conferring in vivo Metabolic Resistance to a Highlt Sele	University of Cincinnati	1010967		CA185370	93.396	0	22.050	22.050
	Contenting in two wetabolie resistance to a right ope	University of Unioninati	1010307	Cancer Biology Research Total	OATOSTO		0	1,328,447	1,328,447
Cancer Cause and Prevention Research	Fanconi Anemia and HPV Transformation				CA102357	93.393	0	(5,255)	(5,255)
	Role and Regulaton of the Human DEK Proto-Oncogene			University of Cincinnati	CA116316	93.393	1,915	270,465	272,379
	Pediatric Emergency Department Decision Support System			The University of Arizona	CA184337	93.393	25,735	190,510	216,245
	The role of Bioactive Lipids in Inflammation and Cancer	Mayo Clinic	CIN-179918-05		CA077839	93.393	0	197,563	197,563
	Molecular Epidemiology of Pediatric Germ Cell Tumors	University of Minnesota	N002118602	Cancer Cause and Prevention Research	CA151284	93.393	27.649	18,686 671,969	18,686 699,618
				Cancer Cause and Prevention Research	Total		27,049	671,969	099,010
Cancer Detection and Diagnosis Research	Genotype and phenotype of chemoresistant AML				CA168369	93.394	0	(2,695)	(2,695)
	Effect of different MRgHIFU approaches on anti-tumor res				CA201918	93.394	0	17,739	17,739
				Cancer Detection and Diagnosis Resear	ch Total		0	15,044	15,044
Cancer Research Manpower	p130 and Pim-1 as prognostic biomarkers and therapeutic				CA189685	93.398	0	52,603	52,603
Cancel Acada of Manpower	Patient Preferences & Adherence in Adolescents and You				CA200668	93.398	0	12,420	12.420
	Training Program In Cancer Therapeutics	University of Cincinnati	1012116		CA117846	93.398	0	112,413	112,413
	Hannig Hogian in Gardor Histopoatoo	childrenty of childrinian	1012110	Cancer Research Manpower Total	0,111010	00.000	0	177,436	177,436
				ouncer research manpower rotar			v		111,400
Cancer Treatment Research	COG Group Chair Award - Scientific Leadership				CA098543	93.395	0	182	182
	Improved therapeutic approaches for hematological disord				CA155091	93.395	0	254,003	254,003
	Nonadherence: Undermining health outcomes in pediatric H			Children's Hospital of Philadelphia	CA157460	93.395	63,278	274,881	338,159
	Targeted Improvement in Stem Cell Therapy for Leukemia				CA157537	93.395	0	20,981	20,981
	Assessing the Therapeutic Window for Future Anti-Notch				CA163653	93.395	0	325,322	325,322
	Developing Novel STAT5 Protein Inhibitors for treatment			University of Toronto	CA186945	93.395	64,793	124,078	188,871
	Targeting Cdc42 for bone marrow transplant therapies				CA193350	93.395	0	389,986	389,986
	Novel therapeutics of targeting mTOR pathway in T-cell I				CA198358	93.395	0	190,038	190,038
	Medulloblastoma and PNET Outcomes Across Three Decades	St Jude's Children's Hospital	111287220-7686261		CA055727	93.395	0	198,288	198,288
	Pediatric Brain Tumor Consortium (PBTC)	St Jude's Children's Hospital	110068185-7707905		CA081457	93.395	0	139,925	139,925
	Palliative Cancer Care: Music Video for AYA-Parent Commu	Indiana University P2D Bioscience	5R01CA162181 1R43CA176907		CA162181 CA176907	93.395 93.395	0	14,359 (9,104)	14,359 (9,104)
	Targeting the Core Binding Factor Tumor Suppressor in ML COG NCTN Network Group Operations Center - scientific	Children's Hospital of Philadelphia	U10CA180886		CA176907 CA180886	93.395	0	(9,104) (11,109)	(9,104) (11,109)
	COG NCTN Network Group Operations Center - Scientific	Children's Hospital of Philadelphia	01004100000	Cancer Treatment Research Total	CATBOBOO	53.353	128,071	1,911,830	2.039.901
Cardiovascular Diseases Research	Molecular pathways controlling cardiac gene expression				HL060562	93.837	0	264,652	264,652
	Signaling Processes Underlying Cardiovascular Function			University of Cincinnati	HL069779	93.837	90,403	1,481,522	1,571,924
	Twist 1 regulation of valve progenitors				HL082716	93.837	0	176,979	176,979
	Targeting of B-AR/GBy signaling in the heart with small Wnt signaling in heart valve development and disease				HL091475 HL094319	93.837 93.837	0	(71,538) 202,219	(71,538) 202,219
					HL094319 HL098691	93.837	0		
	Role of Chromatin and Gene Poising ni T Cell Differentia Admixture Mapping in African Amerian Asthmatic Children				HL103165	93.837	0	(1,702) 18.512	(1,702) 18.512
	National Biological Sample and Data Repository for PAH			Baylor College of Medicine.	HL105333	93.837	2,005	1,341,452	1,649,018
	National Biological Sample and Data Repository for PAH			Boston University	HL105555	93.037	12,005	1,341,432	1,049,010
				Case Western Reserve University			7.840	0	0
							5,156	0	0
				Childrens Hospital Colorado Columbia University.			13,160	0	0
							5,320	0	0
				Duke University East Carolina University			5.820	0	0
				Houston Methodist Research Inst.			10.660	0	0
				Indiana University Health			10,640	0	0
				Inova Healthcare Service			9,800	0	0
				LA Biomed			9,120	0	0
				LSU Health Sciences/Shreveport			1,520	0	Ő
				LSU Health Sciences/Shreveport			1,520	0	0
				LSU Health Sciences/Shreveport Mayo Clinic Jacksonville			1,520 4,560	0	0
				LSU Health Sciences/Shreveport Mayo Clinic Jacksonville Mayo Clinic Rochester			1,520 4,560 28,120	0 0 0	0 0 0

See Notes to Schedule of Expenditures of Federal Awards.

Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
					The Ohio State University			8,360 19,240	0	C
					The University of Arizona Tufts Medical Center, Inc			19,240 2,280	0	
					University of Cincinnati			22,590	0	
					University of Colorado			26,600	0	0
					University of Iowa			1,520	ő	Č
					University of Minnesota			8,360	0	C
					University of Pittsburgh			17,480	0	
					University of Rochester			25,455	0	
					Vanderbilt University			16,720	0	(
					Washington University			2,960	0	(
					Wayne State University	1.1. 105501	~~~~	7,600	0	(
		Accelerated CV Aging in Youth Related to CV Risk Factor				HL105591 HL105924	93.837 93.837	0	158,349 605,401	158,349 605,40
		Thrombospondin 4 regulates adaptive ER stress response Molecular Mechanisms of Arterial-Venous Differentiation				HL105924 HL107369	93.837	0	301.753	301.75
		Hybrid ImmunoTherapy (ATG/Dexamethasone/Etoposide) for H			Phoenix Children's Hospital	HL107309	93.837	2,000	152,644	154,64
		Ameliorating Sickle Nephropathy and Pulmonary Hypertensi			Emory University	HL108752	93.837	2,000	(10,635)	23,98
		Amenorating Stokie Nephropathy and Pullionary hypertensi			University of Illinois at Chicago	TIE 1007 52	55.057	29.140	(10,033)	23,50
					University of Louisville			5,225	0	
		A Mouse model of Barth syndrome, a mitochondrial cardiol			chirolohy of Edulothio	HL108867	93.837	0,220	166,099	166.099
		Pediatric Heart Network Prairieland Consortium			Indiana University	HL109673	93.837	187,362	282,481	469,843
		The Role of COX2 in the Progression of Human and Mouse C			-	HL110390	93.837	0	99	99
		Time-Resolved 129Xe Ventilation-Perfusion MRI in Models				HL111217	93.837	Ō	127,724	127,724
		A Network-based Approach to Associate HDL Subspeciation			University of Cincinnati	HL111829	93.837	86,520	465,136	551,656
		Coup-tf dependent mechanisms of ventricular and hemangio				HL112893	93.837	0	313,038	313,038
		Cincinnati Children's Summer Medical Student Respiratory				HL113229	93.837	0	20,367	20,367
		Passive stretch of the chest wall in patients with Conge			Children's Hospital of Philadelphia	HL113390	93.837	45,761	129,991	175,75
		Cell Signaling Mechanisms of Calcific Aortic Valve Disea				HL114682	93.837	0	268,335	268,33
		Molecular mechanisms underlying upper airway patterning				HL115447	93.837	0	121,580	121,58
		Genetics, Mechanisms and Clinical Phenotypes of Arrhythm			Beth Israel Deaconess Medical Cnt	HL116906	93.837	322,572	163,487	1,673,446
					Boston University			32,710	0	C
					Duke University Good Samaritan Hospital.			300 12.070	0	0
					Johns Hopkins University			45.111	0	
					Loyola University Chicago			45,111	0	0
					The University of Arizona			256,733	0	0
					University of Colorado			213,261	0	0
					University of Pennsylvania			500	0	0
					University of Rochester			626,303	0	0
		Venous Malformations (VM): A Murine Mdoel to Idnetify Th				HL117952	93.837	0	556,998	556,998
		Understanding the Role of HDL Subspecies in Adolescents				HL118132	93.837	0	155,677	155,677
		MBNL1's function in myofibroblast transformation and fib				HL119353	93.837	0	10,952	10,952
		Omics of Lung Diseases				HL119986	93.837	0	256,385	256,385
		Childhood CV Risk and Adult CVD Outcomes: an Internation			Tulane University	HL121230	93.837	735,551	836,766	2,568,346
					University of Cincinnati			28,672	0	C
					University of Iowa			391,931	0	C
					University of Minnesota			431,344	0	C
					University of Tasmania			46,185	0	C
					University Of Turku			97,898	0	C
		BEX1 and the control of protein translation in cardiac h				HL121284	93.837	0	55,551	55,551
		Matrix fibroblasts are required for alveolar homeostasis				HL123969	93.837	0	308,542	308,542
		The role of thrombospondin-4 in the secretory pathway, e Validation of aneurysm associated genes in a zebrafish m				HL124698 HL124889	93.837 93.837	0	56,959 47,808	56,959 47,808
		Validation of aneurysm associated genes in a zebratish m Understanding Cardiovascular Disease Mechanisms				HL124889 HL125204	93.837 93.837	0	47,808 289.951	47,808 289.951
		Preventing rapid decline in CF: statistical research car				HL125204 HL125954	93.837	0	150.743	150.743
		RLDC: Molecular Pathway-Driven Diagnostics & Therapeutic			Columbia University	HL125954 HL127672	93.837	388	500,449	1,021,482
		REDC. Molecular Partway-Driven Diagnostics & Therapeutic			University of Cincinnati	HL12/0/2	93.037	182,639	500,449	1,021,402
					University of South Florida			60.504	0	0
					University of South Fiorida			277,501	0	0
					Vanderbilt I Iniversity					50.000
		The Role of Sca-1+ and ABCG2+ Cardiac Progenitor Cells i			Vanderbilt University	HI 128083	93 837	277,501	56 263	
		The Role of Sca-1+ and ABCG2+ Cardiac Progenitor Cells i Therapeutic Response Evaluation and Adherence Trial: A P			Vanderbilt University	HL128083 HL128885	93.837 93.837	0	56,263 104,442	56,263 104,442
		Therapeutic Response Evaluation and Adherence Trial: A P			Vanderbilt University	HL128083 HL128885 HL129736	93.837 93.837 93.837	0	56,263 104,442 10,000	56,263 104,442 10,000
		Therapeutic Response Evaluation and Adherence Trial: A P 27th Annual Workshop on MR Angiography			Vanderbilt University	HL128885 HL129736	93.837 93.837	0	104,442 10,000	104,442 10,000
		Therapeutic Response Evaluation and Adherence Trial: A P			Vanderbilt University	HL128885	93.837	0 0 0	104,442	104,442
		Therapeutic Response Evaluation and Adherence Trial: A P 27th Annual Workshop on MR Angiography Small molecule targeting of MLK3 for heart failure			Vanderbilt University	HL128885 HL129736 HL129772	93.837 93.837 93.837	0 0 0	104,442 10,000 255,094	104,442 10,000 255,094
		Therapeutic Response Evaluation and Adherence Trial: A P 27th Annual Workshop on MR Angiography Small molecule targeting of MLK3 for heart failure Administrative Coordinating Center: Cardiovascular Devel			Vanderbilt University	HL128885 HL129736 HL129772 HL131003	93.837 93.837 93.837 93.837	0 0 0	104,442 10,000 255,094 883,601	104,442 10,000 255,094 883,601
		Therapeutic Response Evaluation and Adherence Trial: A P 27th Annual Workshop on MR Angiography Small molecule targeting of MLK3 for heart failure Administrative Coordinating Center: Cardiovascular Devel Cela1 Mediates Stretch-regulated Elastin Remodeling Duri			Vanderbilt University	HL128885 HL129736 HL129772 HL131003 HL131261	93.837 93.837 93.837 93.837 93.837 93.837	0 0 0 0 0 0	104,442 10,000 255,094 883,601 30,850	104,442 10,000 255,094 883,601 30,850
		Therapeutic Response Evaluation and Adherence Trial: A P 27th Annual Workshop on MR Angiography Small molecule targeting of MLK3 for heart failure Administrative Coordinating Center: Cardiovascular Devel Cela 1 Mediates Stretch-regulated Elastin Remodeling Duri Role of GPR116 in Alveolar Homeostasis			Vanderbilt University	HL128885 HL129736 HL129772 HL131003 HL131261 HL131634	93.837 93.837 93.837 93.837 93.837 93.837 93.837	0 0 0 0 0 0	104,442 10,000 255,094 883,601 30,850 40,568	104,442 10,000 255,094 883,601 30,850 40,568
		Therapeutic Response Evaluation and Adherence Trial: A P 27th Annual Workshop on MR Anglography Small molecule targeting of MLK3 for heart failure Administrative Coordinating Center: Cardiovascular Devel Cela1 Mediates Stretch-regulated Elastin Remodeling Duri Role of GPR116 in Alvediar Homeostasis Hippo Signaling in Heart Development and Repair	University of Vermont	23326	Vanderbilt University	HL128885 HL129736 HL129772 HL131003 HL131261 HL131634 HL132211	93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837	0 0 0 0 0 0 0 0	104,442 10,000 255,094 883,601 30,850 40,568 67,338	104,442 10,000 255,094 883,601 30,850 40,568 67,338

See Notes to Schedule of Expenditures of Federal Awards.

Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
		Ca Signaling Domains Programming Cardiac Hypertrophy	University of California	201016453-6		HL080101	93.837	0	337,721	337,721
		NHLBI Progenitor Cell Biology Consortium Bioinformatics	University of Maryland (College Park)	101330A		HL099997	93.837	0	213,658	213,658
		Improving Cardiac Function after Myocardial Infarction Cardiac Biomarkers in Pediatric Cardiomyopathy	Temple University	390472-04730-02 WSU14110-A1		HL108806 HL109090	93.837 93.837	0	468,168 32,913	468,168 32,913
		Validation of Circulating Endothelial Cells and Micropar	Wayne State University University of Minnesota	N000226201		HL109090 HL110957	93.837	0	32,913	32,913
		Genotype-Phenotype Associations in Pediatric Cardiomyopa	Wayne State University	WSU10696		HL110957 HL111459	93.837	0	352,698	352,698
		Mechanisms of Refractory Hypertension	University of Alabama-Birmingham	000502641-001		HL113004	93.837	0	25,891	25,891
		Role of Ca2+ Flux through TRP Channels in Cardiac Stress	Temple University	361065-04730-02		HL119229	93.837	0	14,927	14.927
		Development of a Method to Store Refrigerted platelets f	Cleveland Clin Lerner Col of Med	655-SUB / 621-SUB		HL119810	93.837	ů 0	272,453	272,453
		Understanding Quality and Costs in Congenital Heart Surg	University of Michigan	3003050899		HL122261	93.837	0	17,970	17,970
		Genetic Modifiers of Transfusional Iron Overload	Baylor College of Medicine	102150100		HL123641	93.837	0	13,872	13,872
		Impact of Treatment of Mild Sleep-Disordered Breathing o	Children's Hospital of Philadelphia	3210920616		HL125295	93.837	0	127,667	127,667
		Data Coordination and Integration Center for LINCS-BD2K	Icahn School of Medicine @ Mt Sinai	0255-7875-4609		HL127624	93.837	0	50,487	50,487
					Cardiovascular Diseases Research Total	1	-	4,516,799	13,477,043	17,993,842
	Centers for Disease Control and Prevention Investigations & Technical Assistance	Collaboration between WIC and EHDI to Improve Follow-up				DD001007	93.283	0	29,726	29,726
		Hemophilia Prevention Network	Hemophilia Foundation of Michigan	15-16-433		DD000862	93.283	0	22,261	22,261
					Centers for Disease Control & Preventio	n Investig. & Tech. Assistance Total		0	51,987	51,987
	Child Health and Human Development Extramural Research	Pediatric Scientist Development Program (PSDP) [K12]			Children's Hospital Boston	HD000850	93.865	234,406	326,865	1,566,448
					Children's Hospital of Philadelphia			72,208	0	0
					Columbia University			174,972	0	0
					Duke University			92,455	0	0
					Stanford University			25,430	0	0
					University of California			351,706	0	0
					University of Colorado			51,494	0	0
					University of Washington			69,413	0	0
					Washington University			167,498	0	0
		The Role of Human Milk in Infant Nutrition and Health				HD013021	93.865	0	(59,723)	(59,723)
		NICHD Cooperative Multicenter Neonatal Research Network				HD027853	93.865	0	304,300	304,300
		Child Health Research Career Development Award (K12)			One Wester Deserve University	HD028827	93.865	0	381,234	381,234
		Long Term Functional Outcomes Following Early Childhood Ectoderm Formation in the Early Xenopus Embryo			Case Western Reserve University	HD042729 HD045737	93.865 93.865	52,885 0	(7,804) 99,705	45,081 99,705
							93.865	0		(22,850)
		Parental Adherence to CF Homecare: Research Chaplaincy C			University of Onlynny	HD062642 HD064556	93.865	0 222.831	(22,850) 587,439	(22,850) 810,270
		Xenbase: The Xenopus model organism database Transcriptional Control of Human Placental Differentiati			University of Calgary	HD064556 HD065339	93.865	222,831	220,566	220,566
						HD065339 HD066115	93.865	0	220,566	220,566
		Injury Prevention in a Home Visitation Population Telehealth Enhancement of Adherence to Medication in Ped			Children's Hospital of Philadelphia	HD066115 HD067174	93.865	49.447	308,326	354,188 464,489
		releneatin Enhancement of Adherence to Medication in Ped			Children's Hospital of Philadelphia Children's Mercy Hospital	HD007174	93.003	14,449	306,320	404,409
					University of California			57.854	0	0
					University of Pittsburgh			34,413	0	0
		Enhancing treatment adherence and health outcomes			onnoidity of Fittaburgh	HD068223	93.865	0 1,1 10	249,892	249,892
		Using SNA to Examine the Long-Term Outcomes of Socially			University of Kentucky	HD068315	93.865	7,372	(12,447)	(5,075)
		Insulin-like Growth Factor 1 Gene Therapy; Correction of			Shirtsishy of Hondoxy	HD068504	93.865	0	315,239	315,239
		Molecular signaling in uterine receptivity to implantati				HD068524	93.865	0	203,679	203.679
		Cincinnati Pediatric Clinical Pharmacology Postdoctoral				HD069054	93.865	0	152,356	152,356
		Engaging Fathers in Home Visitation: Incorporation of a			The Pennsylvania State University	HD069431	93.865	79,813	442,159	521,972
		Novel RF Coils and k-t Space Imaging for Neonatal Chest				HD071540	93.865	0	89,379	89,379
		Physician Attitudes toward New Biomedical HIV Prevention				HD072807	93.865	0	124,151	124,151
		Initiation and Progression of Preterm Lung Injury with V			University of Western Australia	HD072842	93.865	42,364	124,973	260,608
		Supporting Treatment Adherence Regimens in Pediatric Epi			Saint Louis University	HD073115	93.865	93,270	0 449,081	0 449,081
		Abused and non-abused females' high-risk online behavior				HD073115 HD073130	93.865	0	537,982	537,982
		Shared Decision Making In Pediatric Chronic Conditions:				HD073130	93.865	0	117.169	117.169
		Rare Genetic Variants as Novel Causes of Idopathic or Sy				HD073149 HD073351	93.865	0	153,826	153,826
		Efficacy of Methylphenidate for Management of Long-term				HD074683	93.865	0	129,346	129,346
		Self-Management Assistance for Recommended Treatment (SM				HD074883	93.865	0	33,769	33,769
		Decreasing teen STI prevalence through universal emergen	-			HD075751	93.865	0	127.833	127.833
		Bone Mineral Accretion in Young Children			Children's Hospital of Philadelphia	HD076321	93.865	421,980	506,626	1,128,121
		· ·			University of California			199,515	0	0
		Mechanisms of postnatal cutaneous afferent development d				HD077483	93.865	0	7,447	7,447
		Maternal temperament, stress, and inflammation in preter			University of California - Davis	HD078127	93.865	166,113	294,510	460,622
		Roles of STAT5b in IGF-1 Production and Human Growth				HD078592	93.865	0	325,744	325,744
		Research on Children in Miliary Families: The Impact of			Ryerson University	HD079899	93.865	25,994	141,498	203,230
					University of Cincinnati			35,738	0	0
		The role of Na+, K+-ATPase function in Creatine Transpor			University of Cincinnati	HD080910	93.865	8,760	134,632	143,392
		Treatment of sleep disturbances in school-age children w				HD082307	93.865	0	193,343	193,343
		Morphine Pharmacogenomics to Predict Risk of Respiratory				HD082782	93.865	0	149,969	149,969
		Web-based Intervention to Improve Executive Functioning				HD083335	93.865	0	41,387	41,387
See Notes to Schedule of	Expenditures of Federal Awards.									(Continued)
										·····/

Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
		An Intervention to Reduce SHS Exposure among Pediatric E			San Diego State University	HD083354	93.865	4,300 20,213	324,722	349,236
		Improving ADHD Teen Driving by Targeting Visual Inattent			The University of Arizona	HD084430	93.865	20,213	19,382	0 19,382
		Role of commensal bacteria in regulating neutrophil-medi				HD084686	93.865	0	137,027	137,027
		SCThrive: Improving Self-Management in Adolescents with				HD084810	93.865	0		16,996
		Maitenance, Analysis and Dissemination of CMIND Database				HHSN275201400002C	93.865	0		75,804
		The role of environment in recovery from experimental TB	University of Pittsburgh	0024922 (127439-6)		HD001097	93.865	0	106,707	106,707
		ATN Coordinating Center	University of Alabama-Birmingham	000388010-014		HD040533	93.865	0	30,196	30,196
		Bisphenol A and Gestational Diabetes	University of Cincinnati	1011291		HD051953	93.865	0		246,069
		Pediatric HIV/AIDS Cohort Study (PHACS 3)	Tulane University	TUL-HSC-554718-16/17		HD052104	93.865	0		13,382
		Reading ICARD: Interventions for Children with Attention	Univ of Texas Hith Science Ctr-Houston	0007774B 901461-CCHMC		HD060617 HD060997	93.865 93.865	0		84,983 38.370
		Clinical Decision Rules to Discriminate Bruising Caused Sterol and Isoprenoid Diseases Rare Diseases Consortium	Lurie Children's Hospital of Chicago University of Nebraska	34-5321-2003-607		HD060997 HD061939	93.865	0		38,370
		Pediatric Adverse Reaction in NASH	Arizona State University	5R01HD062489		HD062589	93.865	0		(231)
		Inborn Errors of Metabolism Collaborative: Defining the	Michigan Public Health Institute	K-30209-116-504200		HD069039	93.865	0		21,331
		Production, Validation and Distribution of the Xenopus O	University of Virginia	GC12099 138798		HD069352	93.865	ō	85.531	85,531
		Impact of Emergency Department Probiotic Treatment of Pe	Washington University	WU-14-231		HD071915	93.865	0	(198)	(198)
		Health & wellbeing of sexually abused females & offsprin	Pennsylvania State University	5016-CCHMC-DHHS-2468		HD072468	93.865	0	132,075	132,075
		Deciphering the gene regulatory network controlling vert	University of California	2013-2975		HD073179	93.865	0	122,806	122,806
		Short-term Outcomes of Genitoplasty in DSD	University of Oklahoma	RS20130769-02A3		HD074579	93.865	0		5,723
		Pilot study to develop a Pediatric Cervical Spine Injury	Nationwide Children's Hospital	82039314		HD076108	93.865	0		30,882
		Systematic improvement of Xenopus gene annotations and r	University of California-Berkeley	00008617		HD080708	93.865	0		50,665
		RNA Biosignatures: A Paradigm Change for the Management	Wayne State University	WSU16023-A1		HD085233	93.865	0		3,869
		NBSTRN: Newborn Screening Translational Research Network	American College of Medical Genetics	HHSN275201300001C:004		HHSN275201300011C	93.865	0		502,695 12.368.967
					Child Health and Human Development Ex	tramural Research Total		2,776,894	9,592,073	12,368,967
	Developmental Disabilities Basic Support and Advocacy Grants	Technical Assistance and Training for Maryland Project S				Project SEARCH	93.630	0	13,171	13,171
					Developmental Disabilities Basic Support	and Advocacy Grants Total	_	0	13,171	13,171
	Diabetes, Digestive, and Kidney Diseases Extramural Research	Research Training in Pediatric Nephrology				DK007695	93.847	0	18 944	48.944
	Diabetes, Digestive, and ridincy Diseases Extramular research	Pediatric Gastroenterology and Nutrition Training Grant				DK007727	93.847	0		401,762
		Clinical Center for Cholestatic Liver Disease in				DK062497	93.847	0		(6,859)
		Research Training in Child Behavior and Nutrition				DK063929	93.847	ő		238,409
		Immunologic Dysfunction in Biliary Atresia				DK064008	93.847	0		326,273
		Self-Management of Type 1 Diabetes During Adolescence			Nemours Children's Clinic	DK069486	93.847	82,707	363,243	589,187
					University of Miami			109,122	0	0
					Stanford University			34,115	0	0
		Molecular basis of digestive system development in Xenop			University of Cincinnati	DK070858	93.847	16,193		424,864
		Teen Longitudinal Assessment of Bariatric Surgery (Teen-			Baylor College of Medicine	DK072493	93.847	64,584	573,783	791,791
					Research Inst. at Nationwide Hos			41,905	0	0
					University of Alabama-Birmingham			24,637 20,130	16,996 75,804 106,707 30,196 246,069 13,382 84,983 38,370 17,498 (231) 21,331 85,531 (198) 132,075 122,806 5,573 30,882 502,695 9,552,073 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171 13,171	0
					University of Pittsburgh University of Washington			66,752	0	0
		Digestive Health Center: Bench to Bedside Research in Pe			University of washington	DK078392	93.847	00,752	1 204 014	1,204,014
		Adolescent Bariatric Surgery: Weight and Psychosocial Ri			Neuropsychiatric Res. Institute	DK080020	93.847	34.538		356.644
		Inhibition of an apical cAMP/cGMP transporter (MRP4) in			St Jude Children's Hospital	DK080834	93.847	16.289		312,559
					University of Tennessee			2,978	0	0
		Clinical Center for Cholestatic Liver Disease in Childre			,	DK062497	93.847	0	561,285	561,285
		Control of Diabetes by Manipulation of Bc12 Family Membe				DK081175	93.847	0	32,056	32,056
		DNA Damage and Response in the Bladder Microenvironment.				DK081737	93.847	0		(1,323)
		Mechanisms of Intestinal Stem Cell Expansion Following R				DK083325	93.847	0		1,277
		Biological Basis of Phenotypes and Clinical Outcomes in				DK083781	93.847	0		486,860
		Efficacy of enteral glutamine in reducing bloodstream in			University of Michigan	DK088027	93.847	324		32,046
		Cardiovascular Disease in Children with Chronic Kidney D				DK090070	93.847	0		175,495
		Eosinophil:M2 Macrophage:CCL11 Axis in Experimental Coli Cincinnati Center for Excellence in Molecular Hematology				DK090119 DK090971	93.847 93.847	0		224,829 668,982
		Clinic and Home Family Based Behavioral Treatment for Ob				DK090971 DK091251	93.847 93.847	0		555.776
		The Molecular Determinants of Virus Induced Biliary Atre				DK091251 DK091566	93.847	0		276,253
		Human Endocrine Cell Development				DK092456	93.847	0		426.773
		LPA2 receptor-containing complexes in regulating secreto				DK0932430	93.847	0		314,488
		Epigenetic regulation of intestinal homeostasis				DK093784	93.847	õ		150,380
		Th2 Cytokines and Signaling in Pediatric Inflammatory Bo				DK094832	93.847	0	184,808	184,808
		The Role of Regulatory T Cells in Biliary Atresia				DK095001	93.847	0	351,228	351,228
		Critical Translational Studies in Pediatric Nephrology			University of Cincinnati	DK096418	93.847	77,494	643,304	720,798
		Single Cell/RNA-Seq dissection of Human iPS cell develop				DK098350	93.847	0	383,713	383,713
		Immunopathogenesis of Non-alco				DK099222	93.847	0	413,623	413,623
		Recombineering based analysis of Hox function in kidney				DK099995	93.847	0	358,574	358,574
		NAFLD Improvement after Bariatric Surgery: The role of b			Nemours Children's Clinic, Jacksonville	DK100314	93.847	4,352	592,826	597,179
		Cell Fate Regulation of Nephron Progenitors				DK100315	93.847	0	369,855	369,855
		Outcome of NASH in Adolescents after Bariatric Surgery v				DK100429 DK101618	93.847 93.847	0	444,029 128.627	444,029 128.627
		Wnt/PCP Signaling in the Intestinal Epithelium				DIV101018	93.847	0	128,627	128,627
Con Noton to Schodule of F										

See Notes to Schedule of Expenditures of Federal Awards.

Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
		NAFLD: Mechanisms and Treatments			Baylor College of Medicine.	DK102597	93.847	30,951	333,237	364,188
		Molecular Pathogenesis of MDS			Univ of Texas M D Anderson Cancer	DK102759	93.847	7,559	160,331	167,890
		Regulation of hematopoietic stem cell self-renewal by GT Investigation of Regional Identity in Human Intestinal S			Indiana University Baylor College of Medicine.	DK102890 DK103117	93.847 93.847	16,388 93,035	320,324 302.505	336,713 395,540
		Cdc42, hematopoietic stem cell polarity, and cell fate			Baylor College of Medicine.	DK103117 DK104814	93.847	53,033	182,300	182,300
		Role of the Hypoxia-Inducible Factor-1alpha in Myelodysp				DK105014	93.847	ő	424,351	424,351
		Therapeutic Monitoring and Targeting of Neutrophil Activ				DK105229	93.847	0	156,161	156,161
		The Mechanism Regulating Renal Progenitor Aging				DK106225	93.847	0	46,325	46,325
		Antifungal immunity controlled by commensal bacteria.				DK107199	93.847	0	34,225	34,225
		Role of nuclear IL-33 in mucosal inflammation				DK109573	93.847	0	6,245	6,245
		The Studies to Treat or Prevent Pediatric Type 2 Diabete	George Washington University	13-D06		DK061230	93.847	0	38,171	38,171
		Clinical Research Network in NASH	Cleveland Clin Lerner Col of Med	619-SUB 13-0011		DK061732 DK066143	93.847 93.847	0	242,261 93.059	242,261 93,059
		Chronic Kidney Disease in Children (CKiD III)	Children's Mercy Hospital University of Pittsburgh			DK066143 DK072146	93.847 93.847	0	26,463	26,463
		A Multi-Center Group to Study Acute Liver Failure in Search Nutrition Ancillary Study 2	University of Cincinnati	0019927 (124826-11) 1011141		DK072146 DK077949	93.847	0	12,327	12,327
		Medication Adherence in Children Who Had Liver Transplan	Icahn School of Medicine at Mount Sinai	0255-5001-4609		DK080740	93.847	0	(1,380)	(1,380)
		Progression of Acute Kidney Injury to Chronic Kidney Dis	Yale University	M14A11744 (A10786)		DK082185	93.847	ő	24,989	24,989
		Forecasters of future and progressive chronic kidney	Ohio State University	60040365		DK085673	93.847	ō	(2,548)	(2,548)
		Teen Adherence in Kidney Transplant: Effectiveness of a	The Research Institute of McGill Univers	PT48344		DK092977	93.847	0	87,738	87,738
		A genitoUrinary Development Molecular Anatomy Project (G	Western General Hospital, Human Gen.	R82879		DK092983	93.847	0	54,299	54,299
		The LiverChip - A diagnostic tool for genetic liver dise	Phase 2 Discovery, Inc	5R44DK093214		DK093214	93.847	0	93,671	93,671
		Generating molecular markers that selectively label urot	Columbia University	1 (GG006293-05)		DK094530	93.847	0	51,325	51,325
		Limited Competition for the Continuation of Teen Longitu	University of Cincinnati	1011441	University of Pittsburgh	DK095710	93.847	15,400	735,850	751,250
		Predicting Response to Standardized Pediatric Colitis Th	Connecticut Children's Medical Center	16-179296-04		DK095745	93.847	0	316,722	316,722
		Novel Serum and Urinary Biomarkers of Diabetic Kidney Di	Mount Sinai Hospital	0255-8161-4609		DK096549	93.847	0	14,870	14,870
		Causes and Consequences of Neutrophil Dysfunction in Ear Comprehensive Quantitative Ultrafast 3D Liver MRI	Emory University Case Western University	T151016 RES511409		DK098231 DK098503	93.847 93.847	0	227,430 26.054	227,430 26,054
		FL3X: An Adaptive Intervention to Improve Outcomes for Y	University of North Carolina	5-33709		DK098503 DK101132	93.847	0	597.374	597.374
		Recombinant Erythropoietin Protects Against Kidney disea	Children's Hosp & Reg Med Ct-Seattle	11111SUB		DK101132 DK103608	93.847	0	20.789	20,789
		PancreasCHIP- A diagnostic tool for Inheritable Pancreat	Phase 2 Discovery, Inc	1R43DK105640		DK105640	93.847	0	22,995	22,995
		Limited Competition for the Continuation of the SEARCH f	Wake Forest University	WFUHS114580		DK108175	93.847	0	222,637	222,637
					Diabetes, Digestive, and Kidney Diseases I		-	759,454	16,820,177	17,579,631
	Disabilities Prevention	Improving the Health of People with Disabilities through	Ohio State University	60049492		DD000931	93.184	0	57.092	57.092
				00010102	Disabilities Prevention Total	5500001	-	0	57,092	57,092
	Discovery & Applied Research for Technological Innovations to Improve Human Health	Real-time pediatric cardiovascular MRI without breath ho				EB022405	93.286	0	26,785	26,785
		Center for Point-of-care Technologies Research for Sexua	Johns Hopkins School of Medicine	2003089964		EB007958	93.286	0	139,844	139,844
					Discovery & Applied Res. Technological In	novations to Improve Human Health Total	-	0	166,630	166,630
	Drug Abuse and Addiction Research Programs	Endocannabinoid Signaling during Early Pregnancy			Indiana University	DA006668	93.279	26,169	272,812	298,981
		Tracking Adolescents After Bariatric Surgery; Substance,				DA033415	93.279	0	407,700	407.700
		A revolutionary approach to an efficacious HIV vaccine				DA038017	93.279	0	791,580	791,580
		Ohio Valley Node-Network	University of Cincinnati	1012667		DA013732	93.279	0	14,980	14,980
					Drug Abuse and Addiction Research Progr	ams Total	-	26,169	1,487,072	1,513,240
	Emergency Medical Services for Children	EMS for Children: Pediatric Emergency Care Applied Resea			Washington University	MC22684	93.127	138,555	283,482	565,755
	• •	• ,						143,718	0	0
					Medical College of Wisconsin		_			
					Medical College of Wisconsin Emergency Medical Services for Children	Fotal	-	282,273	283,482	565,755
	Environmental Health	Teratology Training Grant					93 113	282,273		
	Environmental Health	Teratology Training Grant A CommBased Trial to Prevent Lead Poisoning & Iniuries				ES007051	93.113 93.113		267,589	267,589
	Environmental Health	Teratology Training Grant A Comm-Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty:GUF2					93.113 93.113 93.113	0		
	Environmental Health	A CommBased Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty:GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp			Emergency Medical Services for Children	ES007051 ES014575	93.113	0	267,589 (264)	267,589 (264)
	Environmental Health	A CommBased Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty:GUF2			Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019890 ES024713	93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995	267,589 (264) 657,781 598,604 160,588
	Environmental Health	A Comm ¹ . Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty: GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio	University of Cincinnati	008647-051	Emergency Medical Services for Children	ES007051 ES014675 ES019453 ES019890 ES024713 ES006096	93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811	267,589 (264) 657,781 598,604 160,588 25,811
	Environmental Health	A Comm-Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty.GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis	University of Cincinnati	1012228	Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019890 ES024713 ES006096 ES007250	93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643	267,589 (264) 657,781 598,604 160,588 25,811 79,643
	Environmental Health	A Comm. Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmal impact on puberty GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis NIEHS funded Training Program: Molecular Epidemiology in	University of Cincinnati University of Cincinnati	1012228 1012741	Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019453 ES019493 ES006096 ES007250 ES010957	93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643 146,090	267,589 (264) 657,781 598,604 160,588 25,811 79,643 146,090
	Environmental Health	A Comm. Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty:GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis NIEHS funded Training Program. Molecular Epidemiology in Novel ant-Ibrotic mechanisms in chemical-Induced liver	University of Cincinnati University of Cincinnati Michigan State University	1012228 1012741 RC105176CHMC	Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019890 ES024713 ES006006 ES007250 ES010957 ES017537	93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643 146,090 29,723	267,589 (264) 657,781 598,604 160,588 25,811 79,643 146,090 29,723
	Environmental Health	A Comm ² -Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty-GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis NIEHS funded Training Program: Molecular Epidemiology in Novel anti-fibrotic mechanisms in chemical-induced liver Air Pollution, Subclinical CVD and Inflammatory Markers	University of Cincinnati University of Cincinnati Michigan State University University of Maryland (College Park)	1012228 1012741 RC105176CHMC Z036109	Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019800 ES024713 ES006096 ES007250 ES010957 ES010957 ES010587 ES019168	93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643 146,090 29,723 (1,084)	267,589 (264) 657,781 598,604 160,588 25,811 79,643 146,090 29,723 (1,084)
	Environmental Health	A Comm ⁻ . Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty:GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis NIEHS funded Training Program: Molecular Epidemiology in Novel anti-fibrotic mechanisms in chemical-induced liver Air Pollution, Subclinical CVD and Inflammatory Markers Prenatal Sex Steroids, Bisphenol A, Phthalates, and Sexu	University of Cincinnati University of Cincinnati Michigan State University University of Maryland (College Park) Brown University	1012228 1012741 RC105176CHMC Z036109 00000591	Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019890 ES024713 ES000096 ES010967 ES017537 ES017537 ES019168 ES020346	93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014	267,589 (264) 657,781 598,604 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014
	Environmental Health	A Comm. Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty:GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis NIEHS funded Training Program: Molecular Epidemiology in Novel anti-fibrotic mechanisms in chemical-Induced liver Air Pollution, Subclinical CVD and Inflammatory Markers Prenatal Sex Steroids, Bisphenol A, Phthalates, and Sexu Longitudinal study of exposure to PBDEs and PFCs and chi	University of Cincinnati University of Cincinnati Michigan State University University of Maryland (College Park) Brown University University of Cincinnati	1012228 1012741 RC105176CHMC Z036109 00000591 1009253	Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019890 ES024713 ES006096 ES007250 ES017537 ES019168 ES020349	93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014 109,670	267,589 (264) 657,781 598,604 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014 10,014
	Environmental Health	A Comm ⁻ . Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmatil impact on puberty: GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis NIEHS funded Training Program: Molecular Epidemiology in Novel anti-fibrotic mechanisms in chemical-induced liver Air Pollution, Subclinical CVD and Inflammatory Markers Prenatal Sex Steroids, Bisphenol A, Phithalates, and Sexu Longitudinal study of exposure to PBDEs and PFCs and chi Muttiple Risk Factors and Neurodevelopment Deficits in R	University of Cincinnati University of Cincinnati Michigan State University University of Maryland (College Park) Brown University University of Cincinnati University of Cincinnati	1012228 1012741 RC105176CHMC 2036109 00000591 1009253 008148-004	Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019800 ES024713 ES000966 ES010957 ES017537 ES017537 ES019168 ES020346 ES020349 ES021106	93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014 109,670 835	267,589 (264) 657,781 598,604 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014 109,670 835
	Environmental Health	A Comm. Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty:GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis NIEHS funded Training Program: Molecular Epidemiology in Novel anti-fibrotic mechanisms in chemical-Induced liver Air Pollution, Subclinical CVD and Inflammatory Markers Prenatal Sex Steroids, Bisphenol A, Phithalates, and Sexu Longitudinal study of exposure to PBDEs and PFCs and chi Multiple Risk Factors and Neurodevelopment Deficits in R Transgenerational Inheritance of Epigenetic Effects of P	University of Cincinnati University of Cincinnati Michigan State University University of Maryland (College Park) Brown University University of Cincinnati University of Cincinnati University of Cincinnati	1012228 1012741 RC105176CHMC 2036109 00000591 1009253 008148-004 1010899	Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019890 ES024713 ES006066 ES007250 ES010957 ES017537 ES019168 ES020346 ES020346 ES020346 ES020349 ES021106 ES02319	93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014 109,670 835 159,619	267,589 (264) 657,781 598,604 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014 109,670 835 159,619
	Environmental Health	A Comm. Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmal impact on puberty: GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis NIEHS funded Training Program: Molecular Epidemiology in Novel anti-fibrotic mechanisms in chemical-induced liver Air Pollution, Subclinical CVD and Inflammatory Markers Prenatal Sex Steroids, Bisphenol A, Phthalates, and Sexu Longitudinal study of exposure to PBDEs and PFCs and chil Multiple Risk Factors and Neurodevelopment Deficits in R Transgenerational Inheritance of Epigenetic Effects of P Exposure and development of poor bone health among Afric	University of Cincinnati University of Cincinnati Michigan State University University of Maryland (College Park) Brown University University of Cincinnati University of Cincinnati University of Cincinnati University of Cincinnati	1012228 1012741 RC105176CHMC 2036109 00000591 1009253 008148-004	Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019860 ES024713 ES006006 ES010957 ES017537 ES017537 ES01168 ES020349 ES021106 ES020349 ES021106 ES020349 ES0221106	93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643 (160,588 (1,0,588 (1,0,588) (1,0,581) 10,014 10,047 10,670 835 159,619 130,700	267,589 (264) 657,781 598,604 160,588 25,811 79,643 (1,054) 100,014 109,670 835 159,619 130,700
	Environmental Health	A Comm. Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmntl impact on puberty:GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis NIEHS funded Training Program: Molecular Epidemiology in Novel anti-fibrotic mechanisms in chemical-Induced liver Air Pollution, Subclinical CVD and Inflammatory Markers Prenatal Sex Steroids, Bisphenol A, Phithalates, and Sexu Longitudinal study of exposure to PBDEs and PFCs and chi Multiple Risk Factors and Neurodevelopment Deficits in R Transgenerational Inheritance of Epigenetic Effects of P	University of Cincinnati University of Cincinnati Michigan State University University of Maryland (College Park) Brown University University of Cincinnati University of Cincinnati University of Cincinnati	1012228 1012741 RC105176CHMC Z036109 00000591 1009253 008148-004 1010899 1011171	Emergency Medical Services for Children	ES007051 ES014575 ES019453 ES019890 ES024713 ES006066 ES007250 ES010957 ES017537 ES019168 ES020346 ES020346 ES020346 ES020349 ES021106 ES02319	93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014 109,670 835 159,619	267,589 (264) 657,781 598,604 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014 109,670 835 159,619
	Environmental Health	A Comm ⁻ . Based Trial to Prevent Lead Poisoning & Injuries Continued studies of environmnti Impact on puberty:GUF2 Neurobehavioral and Neuroimaging Effects of Traffice Exp Assessing Personal Exposure to Ultrafine PM Number and R Mutigene-environment interactions lead to dilated cardio Environmental Carcinogenesis and Mutagenesis NIEHS funded Training Program: Molecular Epidemiology in Novel anti-fibrotic mechanisms in chemical-induced liver Air Pollution, Subclinical CVD and Inflammatory Markers Prenatal Sex Steroids, Bisphenol A, Phitalates, and Sexu Longitudinal study of exposure to PBDEs and PFCs and chi Muttiple Risk Factors and Neurodevelopment Deficits in R Transgenerational Inheritance of Epigenetic Effects of P Exposure and development of poor bone health among Afric Endocrine Disrupting Chemcais, Thryord Hormones, and Chi	University of Cincinnati University of Cincinnati Michigan State University University of Maryland (College Park) Brown University University of Cincinnati University of Cincinnati University of Cincinnati Brown University	1012228 1012741 RC10516CHMC 2036109 00000591 1009253 008148-004 1010899 1011171 00000782	Emergency Medical Services for Children	ES007051 ES014575 ES01453 ES019890 ES024713 ES000906 ES010957 ES017537 ES019168 ES020346 ES020346 ES020346 ES020349 ES02106 ES023319 ES024074 ES02481	93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113 93.113	0 0 260,786	267,589 (264) 396,995 460,643 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014 109,670 835 159,619 130,700 168,973	267,589 (264) 657,781 598,604 160,588 25,811 79,643 146,090 29,723 (1,084) 10,014 109,670 835 159,619 130,700 168,973

See Notes to Schedule of Expenditures of Federal Awards.

Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
	Extramural Research Programs in the Neurosciences and Neurological Disorders	Mitogenic Activities in Neurofibromatosis				NS028840 NS044080	93.853 93.853	0	292,244 623,737	292,24 623,73
		Roles of Gsx factors in telencephalic neurogenesis Impact of Initial Therapy and Response on Long Term Outc			Children's Research Institute	NS044080 NS045911	93.853	38,639	352,231	419,76
		impact of milital military and tooponoo on Eong form outo			Cook Children's Health Care System	10010011	00.000	1,340	0	110,10
					Montefiore Medical Center			22,177	0	
					NorthShore University HealthSystem			1,706	0	
					Phoenix Children's Hospital			550 2,150	0	
					University of California University of Utah			2,150	0	
		Sodium Channel Gene Variation in the Treatment of Epilep			children of chain	NS062756	93.853	0	14,537	14,5
		mTOR regulation of aberrant neuronal integration and epi				NS062806	93.853	0	468,242	468,
		Identification and reversal of primary and secondary epi				NS065020	93.853	0	299,078	299,
		Imaging the effect of centrotemporal spikes and seizures Longitudinal DTI study in Children Treated for Congenita			University of Alabama-Birmingham	NS065840 NS066932	93.853 93.853	6,916 60,000	454,861 (9,294)	461, 50,
		Molecular control of neurogenesis in the adult subventri			Washington University	NS069893	93.853	00,000	530,017	530
		Molecular Mechanisms of Oligodendrocyte Differentiation				NS072427	93.853	ő	348,696	348
		Regulation of Forebrain Neurogenesis by the Energy Senso			University of Minnesota	NS072591	93.853	12,573	319,400	331
		Chromatin Remodeling Control of CNS Myelination and Remy				NS075243	93.853	0	614,046	614
		Amitriptyline and Topiramate in the Prevention of Childh			Atlanta Headache Specialists, PC	NS076788	93.853	877	922,580	930
					Dallas Pediatric Neurology Associates Eastern Virginia Medical School			1,863 161	0	
					Phoenix Children's Hospital			1.702	0	
					Renown Institute for Neurosciences			2,354	Ő	
					Saint Louis University			595	0	
		A Novel Model of Medulloblastoma to Define Cancer Pathwa				NS078092	93.853	0	265,302	265,
		The toxicity of the RNA CGG repeats in FXTAS				NS078659	93.853	0	60,718	60,
		Aberrant Neuromagnetic Signatures with Chronic Migraine				NS081420 NS083249	93.853 93.853	0	156,938 243	156,
		Characterizing the role of specific Ras proteins in neur Ras Proteins in Nerve Tumorigensis				NS083249 NS083580	93.853	0	375,633	375,
		Novel Combinatorial Therapies for Malignant Peripheral N			Research Inst. at Nationwide Hos	NS084885	93.853	151.020	239.642	390
		Forward Genetic Analysis of Congenital Defects in Cortic				NS085023	93.853	0	493,910	493,
		Brain Mechanisms Supporting Individual Differences in Pa			Virginia Tech	NS085391	93.853	30,590	351,608	382,
		Gaucher disease:Treatment of neurodegenerative disease				NS086134	93.853	0	412,351	412,
		Signaling pathways regulating oligodendrocyte developmen Brain Dysfunction in Neurofibromatosis			Technion Research & Dev Found.	NS088529 NS091037	93.853 93.853	73,905	440,437 229,347	440, 303,
		Impact of targeted granule cell ablation on seizure			recimion Research & Dev Found.	NS092363	93.853	73,905	29,273	29.2
		MicroRNA-mediated silencing of the Kv4.2 complex in epil				NS092705	93.853	0	83.004	83.0
		Synapse elimination in the central nervous system				NS093002	93.853	0	325,536	325,
		MigraineManager: A Self-Management Health Care Resource				NS094476	93.853	0	4,357	4,3
		Cytokine signaling in neurofibroma development		1010100		NS096796	93.853	0	8,313	8,
		Comparison of Hemorrhagic & Ischemic Stroke Among Blacks FMRI in Anterior Temporal Epilepsy Surgery	University of Cincinnati Medical College of Wisconsin	1012498 5R01NS035929	University of Cincinnati	NS030678 NS035929	93.853 93.853	23.688	185,003 16,747	185,0 40,4
		Recanalization Therapies and markers of Outcomes in Acut	University of Cincinnati	005695-051	University of University	NS044283	93.853	20,000	44,147	44.
		Study of Activity-Dependent Sympathetic Sprouting	University of Cincinnati	1012407		NS045594	93.853	0	3,909	3,
		Ultrasound-assisted thrombolysis for stroke therapy	University of Cincinnati	1011436		NS047603	93.853	0	63,823	63,8
		The Establishment of Schwann Cell Polarity and the Infla	University of California	8146sc		NS062796	93.853	0	126,361	126,
		Brain Vascular Malformation Consortium: Predictors of Cl Pilot Trial of Bumetanide for Neonatal Seizures	University of California Children's Hospital Boston	8415sc RSTFD0000591064		NS065705 NS066929	93.853 93.853	0	936 1,172	1
		Mechanisms of TGF regulated fibrosis in muscular dystrop	The University of Chicago	46996-B		NS072027	93.853	0	(46,746)	(46
		Mechanisms of TGF regulated fibrosis in muscular dystrop	Northwestern University	60039007CHMC		NS072027	93.853	0	373,155	373.
		Identification of novel small molecules for CNS myelin r	Texas A & M	06-S140674		NS077215	93.853	0	6,065	6,
		Cincinnati Neuroscience Clinical Trials Research Center	University of Cincinnati	1012613		NS077311	93.853	0	195,996	195
		Potential EEG biomarkers and antiepileptogenic strategie	University of Alabama-Birmingham	000427597-004		NS080199	93.853	0	573	05
		Primary cilia signaling in CNS progenitor cells and thei Early biomarkers of Autism Spectrum Disorders in infants	Massachusetts General Hospital Children's Hospital Boston	220901 RSTFD0000668241		NS080223 NS082320	93.853 93.853	0	85,121 269.629	85 269
		Disordered Regulation of Wnt/?-catenin Signaling in MPNS	University of Minnesota	P00426101		NS086219	93.853	0	215,570	205, 215,
		Targeting the Blood-Brain Barrier in Ischemic Stroke	University of Cincinnati	009662-002		NS088384	93.853	ō	17,936	17,
		Developmental Synaptopathies Associated with TSC, PTEN a	Children's Hospital Boston	RSTFD0000661197		NS092090	93.853	0	121,917	121,
		The Development of Small Molecule Inhibitors for Gaucher	University of Michigan	3003684045		NS092981	93.853	0	191,421	191,4
		Nanovesicle-based intravenous protein/enzyme therapy for	University of Cincinnati	1012136	Extramural Research Programs in Neuros	NS095047 ciences and Neurological Disorders Total	93.853	433,781	72,524 10,652,244	72,5 11,086,0
	Food and Drug Administration Research	Phase II: Vincristine Vs. Sirolimus for High Risk Kaposi				FD004363	93.103	0	187,136	187,
		Annual Meeting of the Neurobeh				FD004852	93.103	0	5,000	5,
		Pharmacokinetic Studies of Tacrolimus in Transplant Pati	University of Cincinnati	1010125		FD004573	93.103	0	129,037	129,0
		Phase-II IDE G090189-11/6/13: Pediatric ICU Patients wit Evaluation of Clinical and Safety Outcomes Associated wi	Innovative BioTherapies, Inc. University of Cincinnati	2015-003 1010884		FD005092 HHSF223201310224C	93.103 93.103	0	54,275 189.072	54,2 189.0
		Evaluation of Chinical and Salety Outcomes ASSOCIATED W	oniversity of Gindminati	1010004		111072202010102240	95.105	0	109,072	169,0

See Notes to Schedule of Expenditures of Federal Awards.

Grants for Training in Primary Care Medicine and Dentistry International Research and Research Training	Faculty Development in Primary Care				HP23195	93.884	0	184.023	184.023
International Research and Research Training								. ,	
International Research and Research Training				Grants for Training in Primary Care Med	licine and Dentistry Total		0	184,023	184,023
	Cellular and Molecular Mechanisms of Alanyl-Glutamine Or				TW008767	93.989	0	115,547	115,547
				International Research and Research Tr	aining Total		0	115,547	115,547
Lung Diseases Research	Lung and Cardiovascular Development and Disease Pathogen				HL007752	93.838	0	238,790	238,790
·	Role of Rb Family in Lung Epithelial Response to Injury				HL079193	93.838	0	(4,722)	(4,722)
	Foxf1 Transcription Factor in Development of Pulmonary C				HL084151	93.838	0	385,392	385,392
	Role of Anti-GM-CSF Antibodies in Myeloid Cell Function				HL085453	93.838 93.838	0	327,686 (41,149)	327,686 (41,149)
	Regulation of Neutrophil Migration and Polarity Transcriptional Programming of Asthma Related Pathology				HL090676 HL095580	93.838	0	(41,149) 567.523	(41,149) 567.523
	Late Preterm Birthe, Ureaplasma Species and Childhood Lu				HL095580 HL097064	93.838	0	(2,180)	(2,180)
	Biomarkers of Immunologic Function and Preterm Respirato				HL101800	93.838	õ	(17,599)	(17,599)
	Genetic Analysis of Murine Chronic Hypoxia-Induced Pulmo				HL102107	93.838	0	1,099	1,099
	The Role of Autophagy in the Pathogenesis of interstitia				HL103923	93.838	0	(33,898)	(33,898)
	Role of SREBP Network in Surfactant Lipid Homeostasis an				HL105433	93.838	0	(16,247)	(16,247)
	Transcriptional Control of Submucosal Gland Formation an				HL108907	93.838	0	(16,046)	(16,046)
	Mechanisms of Dicer1 Function in Lung Organogenesis and				HL109265	93.838	0	289,705	289,705
	Dysregulation of Nrf2 in CF epithelia			Case Western Reserve University	HL109362	93.838	19,296	290,951	310,247
	Airway Progenitor Cell Proliferation and Differentiation			Oregon Health & Science University	HL110964 HL113229	93.838 93.838	199,117 0	353,272 53,747	552,389 53.747
	Ruth L. Kirschstein National Research Service Award Shor Osr transcription factors regulate embryonic lung develo				HL113229 HL114898	93.838	0	53,747 443,108	53,747 443,108
	MR predictors of infection, inflammation, and structural				HL116226	93.838	0	445,108	456.830
	Macrophage Based Gene Therapy for Hereditary Pulmonary A				HL118342	93.838	0	583,277	583,277
	Adolescent Controlled Text Messaging to Improve Asthma M				HL119826	93.838	0	75.854	75.854
	Stard7, a Novel Inhibitor of Allergic Lung Disease				HL122130	93.838	ō	409,005	409,005
	Mechanisms of IL-17A-mediated enhancement of asthma seve				HL122300	93.838	0	380,699	380,699
	"Lung MAP" Atlas Research Center			Cedars-Sinai Medical Center	HL122642	93.838	75,164	613,790	688,954
	Transcriptional regulation of goblet cell metaplasia				HL123490	93.838	0	461,445	461,445
	Transcriptional regulation of pulmonary fibrosis				HL126660	93.838	0	283,752	283,752
	UTE MRI to monitor CF lung disease and response to CFTR	Duda Haliyaalka	2034350		HL131012 HL105702	93.838 93.838	0	83,506 73,106	83,506 73,106
	Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia Severe Asthma Research Program	Duke University Washington University	2034350 WU-16-394		HL105702 HL109257	93.838	0	9,282	9,282
	Simultaneous Xe129 MRI of Regional Lung Ventilation and	University of Virginia	GC12076 145598		HL109257 HL109618	93.838	0	9,282	9,202
	Single Cell NexGen RNA Sequencing of Human	Duke University	203-8676		HL110967	93.838	0	5,507	5,507
	Directed Culturing of Pneumocystis Using Metatranscripto	University of Cincinnati	1012453		HL119190	93.838	0	106.852	106.852
	Deficient Sleep, Lung Functioning, and Functional Outcom	National Jewish Health	20094502		HL119441	93.838	0	26,745	26,745
	Molecular Atlas of Lung Development - Data Coordinating	Duke University	203-8184		HL122638	93.838	0	48,820	48,820
	Characterization of an inhibitory protein complex for cy	University of Tennessee	HL 123535 CCHMC		HL123535	93.838	0	17,841	17,841
	Pathogenesis-Driven Therapeutic Develoment for Pulmonary	University of Cincinnati	1011731		HL127455	93.838	0	45,511	45,511
				Lung Diseases Research Total			293,577	6,517,687	6,811,264
Maternal and Child Health Federal Consolidated Programs	Sickle Cell				MC22218	93.110	0	(14,379)	(14,379)
	Variations in Care and Outcomes for Children with Trauma				MC26806	93.110	0	(4,562)	(4,562)
	Preventive health services and ED utilization among at-r Hemophilia Comprehensive Care	Hemophilia Foundation of Michigan	1-H30MC24047-01-01		MC29447 MC00015	93.110 93.110	0	19,243 21.012	19,243 21.012
	Leadership Education in Neurodevelopmental and Other Rel	University of Cincinnati	1012097		MC00032	93.110	0	617,996	617,996
	Healthy Tomorrows Partnership For Children Program	American Academy of Pediatrics	AAP - Gittelman		MC00032 MC07618	93.110	0	14,389	14,389
	Autism Treatment Network	Massachusetts General Hospital	2UA3MC11054-07-00		MC11054	93.110	0	335.833	335.833
	Development of a Grant Proposal for a Randomized Control	Children's Hospital of Philadelphia	3208960816-P		MC20218	93.110	0	16,362	16,362
	Peer-victimization of adolescents with ASD: Filling the	Univ of California, San Francisco	8637sc		MC28145	93.110	0	17,004	17,004
	-			Maternal and Child Health Federal Cons	olidated Programs Total		0	1,022,899	1,022,899
Medical Assistance Program	Quality Improvement Science - Statewide Quality Improvem	The Ohio State University	G-1415-07-0060-ODM201402		G-1415-07-0060-ODM201402	93.778	0	(1,313)	(1,313)
	Implementation of the BEACON Quality Improvement Data In	The Ohio State University	G-1415-07-0060-ODM201403		G-1415-07-0060-ODM201403	93.778	ō	8.873	8.873
	Progesterone Quality Improvement Project	The Ohio State University	G-1415-07-0060; ODM201404	Aultman Hospital	G-1415-07-0060-ODM201404	93.778	3,244	17,171	41,557
		-		Case Western Reserve University			9,371	0	0
				The Ohio State University			11,770	0	0
	Perinatal Quality Improvement	The Ohio State University	G-1415-07-0060; ODM201405	5	G-1415-07-0060-ODM201405	93.778	0	4,929	4,929
	Partnerships that promote integrated, multidisciplinary	University of Cincinnati	1012298	University the exitate of Olympics	G-1617-05-0003-ODM201609	93.778	0	187,866	187,866
	MedTapp NICU Graduates Project (Federal)	The Ohio State University	G-1617-05-0003-ODM201540		G-1617-05-0003-ODM201540	93.778	48,038	191,619	239,657
	MedTapp QI Science Project (ODM Federal) MedTapp Data Infrastructure (ODM Federal)	The Ohio State University The Ohio State University	G-1617-05-0003-ODM201602 G-1617-05-0003 ODH WISE 1		G-1617-05-0003-ODM201602 G-1617-05-0003-ODM201603	93.778 93.778	0	127,705 403.378	127,705 403,378
	MEDTAPP Progesterone (ODM Federal)	The Ohio State University	G-1617-05-0003 ODH WISE G-1617-05-0003-ODM201604		G-1617-05-0003-ODM201603 G-1617-05-0003-ODM201604	93.778	26,771	403,378 427,686	403,378 562,425
	MEDIAL HOUSERCION (ODMIT GOIL)	the one office onversity	C 1017-00-0000-01201004	The Ohio State University	S-1017-00-0000-0200201004	30.110	107.968	427,000	502,425

See Notes to Schedule of Expenditures of Federal Awards.

Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
-		MEDTAPP Perinatal Project Neonatal Abstinence Syndrome (NAS Federal)	The Ohio State University The Ohio State University	G-1617-05-0003-ODM201605 G-1617-05-0003-ODM201636	Case Western Reserve University Nationwide Childrens Hospital	G-1617-05-0003-ODM201605 G-1617-05-0003-ODM201636	93.778 93.778	0 84,164 40,683	91,863 175,849 0	91,863 300,696 0
					Medical Assistance Program Total			332,009	1,635,626	1,967,635
	Medical Library Assistance	Improving Intensive Care Medication Safety through EHR-b			University of Cincinnati Medical Library Assistance Total	LM012230	93.879	12,729 12,729	167,274 167,274	180,003 180,003
	Mental Health Research Career/Scientist Development Awards	Med Response in Children with Pred Inatt Type ADHD			Mental Health Research Career/Scientist Dev	MH083881 elopment Awards Total	93.281	0	119 119	119 119
	Mantal Haalik Bassayah Cranta	Langituding Assessment of Mania Symptoms (LAMS)				MH073816	02 242	0	598,634	598,634
	Mental Health Research Grants	Longitudinal Assessment of Manic Symptoms (LAMS) Medication Continuity in Children Treated for ADHD				MH083027	93.242 93.242	0	14,737	14,737
		Evaluation of an Intervention for Improving Community-Ba Treatment of Maternal Depression in Home Visitation			Nationwide Childrens Hospital University of Massachusetts Boston	MH083665 MH087499	93.242 93.242	52,051 17,363	109,642 214,537	161,692 231,899
		Molecular Mechanisms Controlling Formation of Basal Gang				MH090740	93.242	0	30,381	30,381
		4/8-Collaborative genomic studies of Tourette Disorder 2/2-Anomalous Motor Physiology in ADHD				MH092520 MH095014	93.242 93.242	0	(2,818) 261,233	(2,818) 261,233
		Executive Function/Metacognitive Training: Early Interve				MH095911	93.242	0	118,684	118,684
		Frontal Cortical Gamma Oscillations Mark Contamination Developing New Technologies to Improve ADHD Medication C				MH100640 MH101155	93.242 93.242	0	183,960 266.013	183,960 266,013
		Latrophilin-3 and ADHD: A new potential mechanism				MH101609	93.242	0	188,133	188,133
		Selective targeting of PI3K to restore higher cognitive Neurobehavioral Effects of Abrupt Methyphenidate Discont			Emory University Seattle Children's Hospital	MH103748 MH105425	93.242 93.242	82,357 279,307	86,636 328,631	168,993 607,939
		A Multi-Method Investigation to Distinguish Sluggish Cog			ocatile officients nospital	MH108603	93.242	2/ 3,507	93,520	93,520
		Cognitive and Behavioral Effects of Sleep Restriction in The effect of lithium on intracellular sodium in brain i	University of Cincinnati	008778-003		MH109787 MH094837	93.242 93.242	0	740 69,235	740 69,235
		Neuroimaging study of risk factors for adolescent bipola	University of Cincinnati	009821-003		MH097818	93.242	0	36,798	36,798
		Multimodal analysis of high-risk psychosis mutations in	Stanford University	60825821-113376		MH104172 MH104311	93.242	0	283,760	283,760
		(ED-STARS) Emergency Dept Screen for Teens at Risk for Movement-Based Mindfulness Training for Children with AD	University of Michigan Kennedy Krieger Research Institute	3003298263 1R21MH104651-01		MH104311 MH104651	93.242 93.242	0	207,520 18,670	207,520 18.670
		Targeting the PI3K Enhancer PIKE to Reverse FXS-associat	Emory University	T267889		MH105353	93.242	0	96,200	96,200
		Risk and resilience factors for frontolimbic connectivit	University of Cincinnati	016227-002	Mental Health Research Grants Total	MH107378	93.242	0 431,078	44,674 3,249,519	44,674 3,680,597
	National Center for Research Resources	General Clinical Research Center				RR008084	93.389	0	(11,798)	(11,798)
		Sweat Patch for Quantification of Lactate in Critically	University of Cincinnati	006141		TR000077	93.389	0	4,983	4,983
		A New Hydrogen Peroxide-Activated Agent that Selectively Cincinnati Ctr for Clin & Trans Sciences & Training	University of Cincinnati University of Cincinnati	006141 006141		TR000077 TR000077	93.389 93.389	0	45,743 (476,314)	45,743 (476,314)
		ononnation of one of nana oblences of maning	University of Unionmati	000141	National Center for Research Resources Tota		=	0	(437,386)	(437,386)
	National Center on Sleep Disorders Research	Pediatric Sleep Research Program				HL078989	93.233	0	64,582	64,582
		Dynamic Computational Modeling of Obstructive Sleep Apne			University of Cincinnati	HL105206	93.233	106,960	43,773	150,733
		Sleep Restriction and the Adolescent Diet: Impact and M Multi-Center Trial of Limiting PGY 2&3 Resident Work Hou	Brigham & Women's Hospital	113170		HL120879 HL111478	93.233 93.233	0	401,624 442,599	401,624 442,599
		-			National Center on Sleep Disorders Research	n Total	-	106,960	952,579	1,059,539
	National Research Service Award in Primary Care Medicine	NRSA Research Fellowship Training			National Research Service Award in Primary	HP10027 Care Medicine Total	93.186	0	375,606 375,606	375,606 375,606
	Nursing Research	Patterned Experience in Preterm Infants			Virginia Commonwealth University	NR012307	93.361	6,538	75,114	81,652
	Nulsing Research	A Clinic-Based Interdisciplinary Intervention for Parent			State of Oklahoma	NR014248	93.361	101,987	491,954	593,941
		REACH: Translational Telehealth HomeCare	Lurie Children's Hospital of Chicago	915342-CCHMC	Number Deserved Total	NR002093	93.361	0	61,650	61,650
					Nursing Research Total			108,525	628,718	737,243
	Oral Diseases and Disorders Research	Molecular Genetic Analysis of Craniofacial Development				DE013681 DE018401	93.121	0	288,893	288,893
		Molecular Patterning of Mammalian Dentition Psychological and physiological correlates of endrogenou				DE018401 DE022368	93.121 93.121	0	568,227 146,350	568,227 146,350
		Large Animal Model for Novel Autologous Treatments of Al				DE023124	93.121	0	134,625	134,625
		The Role of Primary Cilia in Murine Craniofacial Develop Golgb1 in Craniofacial Development				DE023804 DE023864	93.121 93.121	0	422,062 62,704	422,062 62,704
		Understanding and Reducing Variation in Outcomes of Clef				DE025023	93.121	Ő	19,276	19,276
		The role of ectodermal primary cilia in murine orofacial Transcriptome Atlases of the Craniofacial Sutures	Icahn School of Med. at Mount Sinai	0255-7193-4609		DE025537 DE024448	93.121 93.121	0	36,881 14,557	36,881 14,557
		Transonporte Autors Of the Oraniolation outures	isann oonoor or weu, at wount offial	0200-1100-4000	Oral Diseases and Disorders Research Total	52027770	30.121	0	1,693,575	1,693,575
	Poison Center Support and Enhancement Grant Program	Poison Center Support and EnhancementHRSA-14-016CFDA				BHS15468	93.253	0	354,820	354,820
					Poison Center Support and Enhancement Gr	ant Program Total	-	0	354,820	354,820
See Notes to Schedule of E	xpenditures of Federal Awards.									(Continued)

Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
Research on Healthcare Costs, Quality and Outcomes	Acceleration to Expertise: Simulation as a Tool to Impro				HS020455	93.226	0	(178)	(178)
	Pursuing Perfection in Pediatric Therapeutics			Case Western Reserve University	HS021114	93.226	5,067	670,985	680,107
	Pursuing Perfection in Pediatric Theraputics			Children's Hospital Boston	HS022437	00.000	4,056	0 133.875	0 133,875
	Rigor of Multi-Registry CER Studies: Towards Patient-Cen			Hale Manager Otata Analouthural	HS022437 HS022974	93.226 93.226	0 1,431	(2,612)	
	Enhancing the Sustainability of a Pediatric Learning Hea Reduction of Nephrotoxic Medication-Associated Acute Kid			Univ Vermont State Agricultural Children's Hospital Boston	HS022974 HS023763	93.226	26,475	(2,612) 291,468	(1,181) 476,417
	Reduction of Nephrotoxic Medication-Associated Acute Rid			Children's Mercy Hospital	H3023763	93.220	20,475	291,400	476,417
				Nemours Children's Clinic			20,184	0	0
				Seattle Children's Hospital			9,869	0	0
				Spectrum Health Hospitals			21.367	0	0
				Stanford University			24,040	0	0
				University of Alabama-Birmingham			24,040	0	0
				University of California			22,548	0	0
				University of Iowa			18,812	0	0
	Family-Clinician Partnerships to Improve Child Safety in			Oniversity of Iowa	HS023827	93.226	0	141,118	141,118
	Human and system factors contributing to pediatric medic			Emory University	HS024390	93.226	4,368	218,498	232,584
	Haman and eyetern ractore contributing to postatio mode			Research Inst. at Nationwide Hos	110021000	00.220	9.718	210,100	202,001
	Methods and Measures of Improving Healthcare Value			Academy For Healthcare Improvement	HS024249	93.226	20.038	9.731	29,769
	Improving the Quality of Pediatric Emergency Care Using	Northwestern University	60037079 CCHM	Adademy For Heatheare improvement	HS020270	93.226	20,000	54.878	54,878
	Center of Excellence on Quality of Care Measures for Chi	Children's Hosp & Reg Med Ct-Seattle	10965SUB		HS020506	93.226	0	8,329	8,329
	Collaborative Ohio Inquiry Network (COIN)	University of Cincinnati	010028-002		HS021648	93.226	0	3,188	3,188
	Improving Child Health by Disseminating Patient Centered	American Board of Pediatrics Found.	PCOR-YEAR3 NO COST EXTEN	16	HS021935	93.226	0	44,536	44,536
	Effects of Virtual Realty Simulation on Worker Emergency	Wright State University	P0036104	10	HS023149	93.226	0	85,492	85,492
	Encods of virtual reality ofinitiation of worker Energency	Winght Otate Onliversity	1 0000104	Research on Healthcare Costs, Quality and		55.220	229,626	1,659,308	1,888,934
				Research on Healthcare Costs, Quality and	Outcomes Total		229,020	1,059,500	1,000,934
Research Related to Deafness and Communication Disorders	Usher proteins in the inner ear structure and function				DC012564	93.173	0	(4,943)	(4,943)
	Idiopathic auditory dysfunction in children: nature and				DC014078	93.173	0	434,887	434,887
	Wideband Clinical Diagnosis and Monitoring of Middle-Ear	Boys Town National Research Hospital	5R01DC010202		DC010202	93.173	0	(11.637)	(11,637)
	5 5	,		Research Related to Deafness and Commun			0	418,307	418,307
Olabla Onli Tarada and Dava a tadian Davaran	Diable Teacher and Outcomes Descends in the Midward			Oblideeds Usersidel of Managerste	EMC27863	93.365	52,034	500.040	000 407
Sickle Cell Treatment Demonstration Program	Sickle Treatment and Outcomes Research in the Midwest -			Children's Hospital of Minnesota	EMC27863	93.365		596,310	996,167
				Indiana Hemophilia & Thrombosis Ctr			88,229	0	0
				Medical College of Wisconsin			62,439	0	0
				Sickle Cell Disease Assoc of America			103,689	0	0
				University of Illinois at Chicago	00100011010510		93,465	0	0
	Cincinnati Sickle Cell Project	Ohio Department of Health	03130011SK0815	Sickle Cell Treatment Demonstration Progra	03130011SK0512	93.365	399,857	129,249 725,559	129,249 1,125,415
				Sickle Cell Treatment Demonstration Progra			335,007		
Substance Abuse & Mental Health Srvs Projects of Regional & National Significance	The Center for Trauma Recovery and Juvenile Justice (CTR	University of Connecticut Health Center	UCHC6-68919774		SM061273	93.243	0	177,225	177,225
				Substance Abuse & Mental Health Svs Proj	of Reg & National Significance Total		0	177,225	177,225
Training and Clinical Skills Improvement Projects	Enhanced Surveillance for New Vaccine Preventable Diseas				IP000458	93.185	0	150,510	150,510
				Training and Clinical Skills Improvement Pr	ojects Total	-	0	150,510	150,510
Trans-NIH Research Support	Open Source Science: Transforming Chronic Illness Care				DK085719	93.310	0	104,502	104,502
	Establishment of in vitro and in vivo models of human ga				EB021780	93.310	0	196,385	196,385
	Direct Epigenetic Reprogramming of T Cells				GM119134	93.310	0	170,638	170,638
	Characterizing the Gut Microbial Ecosystem for Diagnosis	Broad Medical Research Program	5230121-5500000605		DE023798	93.310	0	(128,788)	(128,788)
			F000400 FF000000F		DK102557	93.310	0	91,073	91,073
	Characterizing the Gut Microbial Ecosystem for Diagnosis	Broad Medical Research Program	5230123-5500000605		DICIO2001				
	Characterizing the Gut Microbial Ecosystem for Diagnosis	Broad Medical Research Program	5230123-5500000605	Trans-NIH Research Support Total	51(10233)	-	0	433,809	433,809
University Centers for Excellence in Dev. Disabilities Education. Res. & Service		-		Trans-NIH Research Support Total		-	0		
University Centers for Excellence in Dev. Disabilities Education, Res. & Service	Characterizing the Gut Microbial Ecosystem for Diagnosis University of Cincinnati University Center for Excellenc	Broad Medical Research Program	008131-006	Trans-NIH Research Support Total University Ctrs Excellence in Dev Disab. Ed	DD0696/01	93.632	0 0 0	433,809 539,574 539,574	433,809 539,574 539,574
	University of Cincinnati University Center for Excellenc	-			DD0696/01 ucation, Res, and Service Total	93.632	0 0 0	539,574 539,574	539,574 539,574
University Centers for Excellence in Dev. Disabilities Education, Res. & Service Vision Research	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins	-			DD0696/01 ucation, Res, and Service Total EY014648	93.632 93.867	0 0 0	539,574 539,574 289,695	539,574 539,574 289,695
	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins Retinal Microglia and Anglogenesis	-			DD0696/01 ucation, Res, and Service Total EY014648 EY021636	93.632 93.867 93.867	0 0 0 0	539,574 539,574 289,695 368,432	539,574 539,574 289,695 368,432
	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins Retinal Microglia and Angiogenesis Molecular Networks Controlling Subtype Specification of	-			DD0696/01 ucation, Res, and Service Total EY014648 EY021636 EY022687	93.632 93.867 93.867 93.867 93.867	0 0 0 0 0 0	539,574 539,574 289,695 368,432 12,477	539,574 539,574 289,695 368,432 12,477
	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins Retinal Microglia and Angiogenesis Molecular Networks Controlling Subtype Specification of EYA in Retinal Angiogenesis	-			DD0696/01 ucation, Res, and Service Total EY014648 EY021636 EY022687 EY0222917	93.632 93.867 93.867 93.867 93.867	0 0 0 0 0 0	539,574 539,574 289,695 368,432 12,477 364,743	539,574 539,574 289,695 368,432 12,477 364,743
	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins Retinal Microglia and Angiogenesis Molecular Networks Controlling Subtype Specification of EYA in Retinal Angiogenesis Defining Gilal Programs that Support Adult Photoreceptor	-			DD0696/01 ucation, Res, and Service Total EY014648 EY021636 EY022867 EY022917 EY022405	93.632 93.867 93.867 93.867 93.867 93.867	0 0 0 0 0 0 0 0	539,574 539,574 289,695 368,432 12,477 364,743 6,173	539,574 539,574 289,695 368,432 12,477 364,743 6,173
	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins Retinal Microglia and Angiogenesis Molecular Networks Controlling Subtype Specification of EYA in Retinal Angiogenesis Defining Glial Programs that Support Adult Photoreceptor SLC25A46 mutations cause optic atrophy, axonal neuropath	-		University Ctrs Excellence in Dev Disab. Ed	DD0696/01 ucation, Res, and Service Total EY014648 EY021636 EY022687 EY022917 EY022917 EY022405 EY026609	93.632 93.867 93.867 93.867 93.867 93.867 93.867	0 0 0 0 0 0 0 0 0 0 0	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680
	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins Retinal Microglia and Angiogenesis Molecular Networks Controlling Subtype Specification of EYA in Retinal Angiogenesis Defining Gilal Programs that Support Adult Photoreceptor	-		University Ctrs Excellence in Dev Disab. Ed	DD0696/01 ucation, Res, and Service Total EY014648 EY021636 EY022867 EY022917 EY022405	93.632 93.867 93.867 93.867 93.867 93.867	0 0 0 0 0 0 0 0 118,842	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680 207,974	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680 326,816
	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins Retinal Microglia and Angiogenesis Molecular Networks Controlling Subtype Specification of EYA in Retinal Angiogenesis Defining Glial Programs that Support Adult Photoreceptor SLC25A46 mutations cause optic atrophy, axonal neuropath	-		University Ctrs Excellence in Dev Disab. Ed	DD0696/01 ucation, Res, and Service Total EY014648 EY021636 EY022687 EY022917 EY022917 EY022405 EY026609	93.632 93.867 93.867 93.867 93.867 93.867 93.867	0 0 0 0 0 0 0 0 118,842 118,842	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680
	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins Retinal Microglia and Angiogenesis Molecular Networks Controlling Subtype Specification of EYA in Retinal Angiogenesis Defining Glial Programs that Support Adult Photoreceptor SLC25A46 mutations cause optic atrophy, axonal neuropath	-		University Ctrs Excellence in Dev Disab. Ed University of California Vision Research Total Case Western Reserve University	DD0696/01 ucation, Res, and Service Total EY014648 EY021636 EY022687 EY022917 EY022917 EY022405 EY026609	93.632 93.867 93.867 93.867 93.867 93.867 93.867	118,842 4,545	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680 207,974	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680 326,816
Vision Research	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins Retinal Microglia and Angiogenesis Molecular Networks Controlling Subtype Specification of EYA in Retinal Angiogenesis Defining Glial Programs that Support Adult Photoreceptor SLC25A46 mutations cause optic atrophy, axonal neuropath Light Regulated Vascular Development of the Eye	-		University Ctrs Excellence in Dev Disab. Ed University of California Vision Research Total	DD0696/01 ucation, Res, and Service Total EY014648 EY021636 EY022887 EY022407 EY022405 EY026609 EY023179	93.632 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867	118,842 4,545 18,313	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680 207,974 1,296,175	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680 326,816 1,415,016
Vision Research	University of Cincinnati University Center for Excellenc Mechanism of action of Retinal Determination proteins Retinal Microglia and Angiogenesis Molecular Networks Controlling Subtype Specification of EYA in Retinal Angiogenesis Defining Glial Programs that Support Adult Photoreceptor SLC25A46 mutations cause optic atrophy, axonal neuropath Light Regulated Vascular Development of the Eye	-		University Ctrs Excellence in Dev Disab. Ed University of California Vision Research Total Case Western Reserve University	DD0696/01 ucation, Res, and Service Total EY014648 EY021636 EY022887 EY022407 EY022405 EY026609 EY023179	93.632 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867	118,842 4,545	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680 207,974 1,296,175 133,115	539,574 539,574 289,695 368,432 12,477 364,743 6,173 46,680 326,816 1,415,016

See Notes to Schedule of Expenditures of Federal Awards.

Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
	Human Genome Research	Better Outcomes for Children: GWAS & PheWAS in eMERGEII. Effect of disease-associated genetic variants on viral p Better Outcomes for Children: Promoting Excellence in He			Children's Hospital Boston	HG006828 HG008186 HG008666	93.172 93.172 93.172	391,451 0 0	27,608 172,952 670,073	419,059 172,952 670,073
	Prevention & Public Hith Fund (Affordable Care Act) Enhanced Surveil. New Vaccine	Enhanced Surveillance for New Vaccine Preventable Diseas			Human Genome Research Total	IP000458	93.533	391,451 0	870,632 896,175 896,175	1,262,084 896,175 896,175
					Prevention & Public Hith Fund (Aff. Care Act			U		
	Alcohol Research Programs	Regulation of hepatic stellate cells in development and Mechanisms of Alcoholic Liver Disease Teen Alcohol Screening in the Pediatric Emergency Care A	Rhode Island Hospital	7017137111-5-OH	University of Cincinnati	AA020514 AA020846 AA021900	93.273 93.273 93.273	0 43,340 0	208,536 878 4,132	208,536 44,218 4,132
	Injury Prevention and Control Research and State and Community Based Programs	STAT-ED - Suicidal Teens Accessing Treatment in the ED			Alcohol Research Programs Total Nationwide Childrens Hospital	CE002129	93.136	43,340 135,170	213,546 34,652	256,886 169,822
					Injury Prevention & Control Res. & State & Community Based Programs Total			135,170	34,652	169,822
	National Center for Advancing Translational Sciences	Generating Human Intestinal Organoids with an ENS. University of Pittsburgh Clinical and Translational Scie Clinical and Translational Science Award Cincinnati Center for Clinical and Translational Science	University of Pittsburgh University of Cincinnati University of Cincinnati	9010902 (125998-6) 009904-003 009905-062		TR000546 TR000005 TR001425 TR001426	93.350 93.350 93.350 93.350	0 0 0 0	(1,200) 46,531 2,148,903 184,366	(1,200) 46,531 2,148,903 184,366
					National Center for Advancing Translational	Sciences Total	•	0	2,378,599	2,378,599
	Occupational Safety and Health Program	Just-in-Time Methods for Understanding Near-misses, Inju Genetic Susceptibility for Occupational Asthma Early Identification of World Trade Center Conditions in	University of Cincinnati New York University	008802-004 12-02599		OH010035 OH008795 OH010394	93.262 93.262 93.262	0 0 0	53,943 26,406 14,167	53,943 26,406 14,167
					Occupational Safety and Health Program To			0	94,517	94,517
	Research and Training in Complementary and Alternative Medicine	DNA Attenuates Inflammatory Responses through Altering R	The Research Instit at Nationwide Hosp	726413	Research and Training in Complementary ar	AT006880 ad Alternative Medicine Total	93.213	0 0	18,203 18,203	18,203 18,203
	HIV Prevention Activities_Health Department Based	HIV Testing in Ohio Emergency Departments			HIV Prevention Activities_Health Departmen	03130012HT0314 t Based Total	93.940	0	46,943 46,943	46,943 46,943
	Hospital Prep Prog (HPP) & Public Hith Emerg. Prep (PHEP) Aligned Cooperative Agrmnts	Ohio Poison Control Bioterrorism Grant FY15			Research Inst. at Nationwide Hos Hosp. Prep Prog (HPP) & Public Hith Emerg.	03130012PP0415 Prep (PHEP) Coop. Agrmts Total	93.074	96,690 96,690	78,862 78,862	175,552 175,552
	Health Program for Toxic Substances and Disease Registry	UIC PEHSU PROGRAM-2013-05487-01-00 KN UIC PEHSU agreement - Meeting the Environmental Health N	Univ of Illinois @ Chicago Univ of Illinois @ Chicago	1U61TS000118 1U61TS000237	Health Program for Toxic Substances and D	TS000118 TS000237 isease Registry Total	93.161 93.161	0 0 0	(269) 13,028 12,759	(269) 13,028 12,759
	Microbiology and Infectious Diseases Research	Norovirus Capsid: A Novel Drug Target. HBGA receptors in host cell entry and infection of norov	University of Cincinnati Purdue University	0087939-003 4102-65270	Microbiology and Infectious Diseases Resea	Al097936 Al111095 rch Total	93.856 93.856	0 0 0	19,436 254,821 274,258	19,436 254,821 274,258
	Cancer Control	Imaging Notch Interactions with Members of Its Pathway	Washington University	WU-17-25	Cancer Control Total	CA094056	93.399	0	171,217 171,217	171,217 171,217
	Healthy Start Initiative	Healthy Start Cincinnati			University of Cincinnati Healthy Start Initiative Total	MC27823	93.926	18,981 18,981	573,132 573,132	592,112 592,112
	Health Care Innovation Challenge	Coordinating all resources effectively for children with	Children's National Medical Center	30002606-04	Health Care Innovation Challenge Total	CMS331335	93.610	0	263,710 263,710	263,710 263,710
	Affordable Care Act (ACA) Family to Family Health Information Centers	Ohio Family to Family Health Information Centers			University of Cincinnati Affordable Care Act (ACA) Family to Family	MC28443 Health Information Centers Total	93.504	2,932 2,932	17,918 17,918	20,850 20,850
	Community Programs to Improve Minority Health Grant Program	Pathways for Emerging Healthcare Leaders	University of Cincinnati	009908-002	Community Programs to Improve Minority I	CPIMP151094 Health Grant Program Total	93.137	0	6,428 6,428	6,428 6,428
					Dept of Health and Human Serv Total		-	15,183,930	115,252,006	130,435,936
Dept of Housing and Urban Dev	Healthy Homes Technical Studies Grants	Efficiency of HEPA Air Purification in Reducing Traffic-	University of Cincinnati	009627-002	Healthy Homes Technical Studies Grants To	OHHHU0027	14.906	0	33,552 33,552	33,552 33,552
					Dept of Housing and Urban Dev Total		-	0	33,552	33,552
					-					

See Notes to Schedule of Expenditures of Federal Awards.

Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Identifying Number	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
Department of Veterans Affairs	Consulting Services	Department of Veterans Affairs VISN10 539-11 (VA PI:Rieg				VA250-14-P-1649	64.033	0	(8,523)	(8,523
		Department of Veterans Affairs VISN10 539-11 (VA PI:Rieg				VA250-15-P-1091	64.033	0	23,271	23,271
		Consulting Services for Assessing and Documenting VA Tra	University of Cincinnati	008612-002 (007974)		VA250-13-C-0058	64.033	0	(1,267)	(1,267
					Consulting Servcies Total			0	13,481	13,481
					Dept of Veterans Affairs Total			0	13,481	13,481
Office of Personnel Management	Intergovernmental Personnel Act (IPA) Mobility Program	CDC IPA - Brad Kurowski				IPA_Kurowski	27.011	0	25,873	25,873
Ū.		VAMC IPA - Sara Lazaro				IPA_Lazaro	27.011	0	49,549	49,549
		VAMC IPA - Albert Magnusen				IPA_Magnusen	27.011	0	63,598	63,598
		VAMC IPA - Diana Taft				IPA_Taft	27.011	0	45,017	45,017
		VAMC IPA - Matthew Weirauch				IPA_Weirauch	27.011	0	5,231	5,231
					Intergovernmental Personnel Act (IPA) Mob	bility Program Total	_	0	189,269	189,269
					Office of Personnel Management Total		-	0	189,269	189,269
Natl Aeronautics & Space Admin	Exploration	Acute and long term outcomes of simulated deep space rad				NNX13AO47G	43.003	0	245,207	245,207
		5			Exploration Total		-	0	245,207	245,207
	Space Operations	RNA Deep Sequencing and Metabolomic Profiling of Microgr	Arizona State University	14-380		NNX13AM01G	43.007	0	25.970	25.970
					Space Operations Total			0	25,970	25,970
					Natl Aeronautics & Space Admin Total		-	0	271,176	271,176
Dept of Homeland Security	Centers for Homeland Security	National Center for Food Protection and Defense	University of Minnesota	P004544803		2010-ST-061-FD000I	97.061	0	5.071	5,071
Sopr of Homolana Cooliny	Control for Homolana Codarty				Centers for Homeland Security Total	2010 01 001 1 2000.		0	5,071	5,071
					Dept of Homeland Security Total		-	0	5,071	5,071
					Sopt of Homoland Coolarty Fotal			Ū	0,011	0,011
EPA / Office of Water	Wetland Prog. Grants - State/Tribal Environmental Outcome Wetland Demonstration Prog.	Hospital Discharge Practices and Contaminants of Emergin	American Water Works Company, Inc.	4616		Project 4616	66.479	0	7,226	7,226
					Wetland Progr. Grants-State/Tribal Environ	m. Outcome Wetland Demo Program Total		0	7,226	7,226
					EPA / Office of Water Total		-	0	7,226	7,226
		Drug and Poison Control					93.959	0	213,124	213,124
					Grand Total		-	45 005 750 /	117 701 000	400 007 505
					Grand Total		\$	\$ 15,205,759 \$	\$ 117,781,830 \$	\$ 132,987,589

See Notes to Schedule of Expenditures of Federal Awards.

(Concluded)

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2016

1. SCOPE OF AUDIT

All federal grant operations of Cincinnati Children's are included in the scope of Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance)*. Single audits under the Uniform Guidance are performed in accordance with the provisions of the Office of Management and Budget (OMB)'s Compliance Supplement for Single Audits of Higher Learning Institutions and other Non-Profit Institutions (the "Compliance Supplement"). The Department of Health and Human Services has been designated as Cincinnati Children's cognizant agency for the single audit.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation — The accompanying Supplementary Schedule of Expenditures of Federal Awards (the "Schedule") includes the federal grant activity of Cincinnati Children's under programs of the federal government for the year ended June 30, 2016, and is presented on the accrual basis of accounting. This is consistent with the basis of accounting used in the preparation of the basic consolidated financial statements. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance).* Because the Schedule presents only a selected portion of the operations of Cincinnati Children's, it is not intended to and does not present the financial position, changes in net assets or cash flows of Cincinnati Children's did not elect to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

Net Asset Balances — Negative amounts represent grants with deficit balances which were closed during fiscal 2016.

* * * * * *



Deloitte & Touche LLP 250 East 5th Street Suite 1900 Cincinnati, OH 45202-5109 USA

Tel:+1 513 784 7100 Fax:+1 513 784 7204 www.deloitte.com

REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

INDEPENDENT AUDITORS' REPORT

To the Board of Trustees of Children's Hospital Medical Center and Affiliates Cincinnati, Ohio

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated balance sheets as of June 30, 2016, and the related consolidated statements of operations and changes in net assets and of cash flows for the years then ended, and the related notes to the consolidated financial statements which collectively comprise Children's Hospital Medical Center and Affiliates ("Cincinnati Children's") basic consolidated financial statements and have issued our report thereon dated October 17, 2016, except for Note 12, as to which the date is January 27, 2017.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered Cincinnati Children's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of Cincinnati Children's internal control. Accordingly, we do not express an opinion on the effectiveness of Cincinnati Children's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Cincinnati Children's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Cincinnati Children's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Cincinnati Children's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Deloitte ? Touche LLP

October 17, 2016, Except for Note 12, as to which the date is January 27, 2017



Deloitte & Touche LLP 250 East 5th Street Suite 1900 Cincinnati, OH 45202-5109 USA

Tel:+1 513 784 7100 Fax:+1 513 784 7204 www.deloitte.com

REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON THE SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE

INDEPENDENT AUDITORS' REPORT

To the Board of Trustees Children's Hospital Medical Center and Affiliates Cincinnati, Ohio

Report on Compliance for Each Major Federal Program

We have audited Children's Hospital Medical Center and Affiliates ("Cincinnati Children's") compliance with the types of compliance requirements described in the U.S. Office of Management and Budget (OMB) Compliance Supplement that could have a direct and material effect on each of Cincinnati Children's major federal programs for the year ended June 30, 2016. Cincinnati Children's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of Cincinnati Children's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principals, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Cincinnati Children's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Cincinnati Children's compliance.

Opinion on Each Major Federal Program

In our opinion, Cincinnati Children's complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2016.

Report on Internal Control Over Compliance

Management of Cincinnati Children's is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Cincinnati Children's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Cincinnati Children's internal control over compliance.

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance requirement of a federal program that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the consolidated financial statements of Cincinnati Children's as of and for the year ended June 30, 2016, and have issued our report thereon dated October 17, 2016, except for Note 12, as to which the date is January 27, 2017, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditure of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Deloitte ? Touche LLP

October 17, 2016, Except for Note 12, as to which the date is January 27, 2017

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2016

PART I. SUMMARY OF AUDITOR'S RESULTS

Financial Statements:

Type of auditor's report issued:		Unmodified	
Internal control over financial repo	rting:		
Material weakness(es) identified?		Yes	<u>X</u> No
Significant deficiency(ies) identif	ied?	Yes	None X reported
Noncompliance material to financi	al statements noted?	Yes	<u> </u>
Federal Awards:			
Internal control over major program	ns:		
Material weakness(es) identified?		Yes	<u> </u>
Significant deficiency(ies) identif	ied?		N
		Yes	None X reported
Type of auditor's report issued on programs:	compliance for major	Unmodified	
Any audit findings disclosed that a accordance with 2 CFR 200.516(a)		Yes	<u>X</u> No
Identification of Major Programs:			
CFDA Number	Name of Federa	l Program or Clust	er
Various	Research and Development*		
	etermined that its entire research and de grant activity should be considered cluste		
	uish between Type A and Type B program tested as a single Type A program		\$ 3,000,000

Auditee qualified as low-risk auditee?

X Yes No

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEARS ENDED JUNE 30, 2016

PART II. FINDINGS RELATED TO THE FINANCIAL STATEMENTS

None

PART III. FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

None